US20060057599A1 - System for autonomous monitoring of bioagents - Google Patents

System for autonomous monitoring of bioagents Download PDF

Info

Publication number
US20060057599A1
US20060057599A1 US11/000,491 US49104A US2006057599A1 US 20060057599 A1 US20060057599 A1 US 20060057599A1 US 49104 A US49104 A US 49104A US 2006057599 A1 US2006057599 A1 US 2006057599A1
Authority
US
United States
Prior art keywords
sample
air
soil
bioagents
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/000,491
Inventor
John Dzenitis
Steve Brown
Billy Colston
Dora Gutierrez
Bruce Henderer
Benjamin Hindson
Ramakrishna Madabhushi
Anthony Makarewicz
Don Masquelier
Mary McBride
Thomas Metz
Shanavaz Nasarabadi
Ujwal Setlur
Sally Smith
Kodumudi Venkateswaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Livermore National Security LLC
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to US11/000,491 priority Critical patent/US20060057599A1/en
Assigned to REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE reassignment REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DZENTIS, JOHN, BROWN, STEVE B., COLSTON, JR. BILLY W., GUTIERREZ, DORA M., HENDERER, BRUCE D., HINDSON, BENJAMIN J., MADABHUSHI, RAMAKRISHNA S., MAKAREWICZ, ANTHONY J., MASQUELIER, DON A., MCBRIDE, MARY T., METZ, THOMAS R., NASARABADI, SHANAVAZ L., SETLUR, UJWAL S., SMITH, SALLY M., VENKATESWARAN, KODUMUDI S.
Assigned to ENERGY, U.S. DEPARTMENT OF reassignment ENERGY, U.S. DEPARTMENT OF CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Publication of US20060057599A1 publication Critical patent/US20060057599A1/en
Assigned to LAWRENCE LIVERMORE NATIONAL SECURITY, LLC reassignment LAWRENCE LIVERMORE NATIONAL SECURITY, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/08Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • G01N1/2211Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling with cyclones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Electro-optical investigation, e.g. flow cytometers
    • G01N15/1456Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • G01N1/2214Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling by sorption
    • G01N2001/2217Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling by sorption using a liquid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • the present invention relates to bioagents and more particularly to monitoring bioagents.
  • the new environmental surveillance system uses monitoring technology and methods developed in part by the Department of Energy's national laboratories. Samples of DNA are analyzed using polymerase chain reaction techniques, which examine the genetic signatures of the organisms in a sample, and make rapid and accurate evaluations of that organism . . . . Officials who helped develop the system said that tests performed at Dugway Proving Ground in Utah and national laboratories showed that the system would almost certainly detect the deliberate release of several of the most dangerous pathogens. ‘Obviously, the larger the release, the greater the probability that the agent will be detected,’ an official said. ‘But given the coverage provided by the E.P.A. system, even a small release, depending on which way the wind was blowing and other meteorological conditions, is likely to be picked up.’”
  • Bio-Watch This technology is now expected to play a large role in the U.S. government's recently unveiled homeland security counter-terrorism initiative, Bio-Watch, which is designed to detect airborne bioterrorist attacks on major U.S. cities within hours. Announced back in January, Bio-Watch is a multi-faceted, multi-agency program that involves the U.S. Department of Energy, the Environmental Protection Agency (EPA), and the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC). Many of the EPA's 3,000 air-quality monitoring stations throughout the country are being adapted with biodetectors to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill, according to the EPA.
  • EPA Environmental Protection Agency
  • CDC U.S. Department of Health and Human Services' Centers for Disease Control and Prevention
  • the nationwide network of environmental monitors and biodetectors which reportedly will eventually monitor more than 120 U.S. cities, is expected to detect and report a biological attack within 24 hours. Citing security reasons, the EPA declined to disclose further details about the program at this time . . . .
  • the Autonomous Pathogen Detection System is a file-cabinet-sized machine that sucks in air, runs tests, and reports the results itself.
  • APDS integrates a flow cytometer and real-time PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins.
  • APDS-II uses bead-capture immunoassays and a compact flow cytometer for the simultaneous identification of multiple biological simulants. Laboratory tests have demonstrated the fully autonomous operation of APDS-II for as long as 24 hours.”
  • the present invention provides an autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents.
  • a collector gathers a quantity of the air, water, soil, or other substance being monitored.
  • the collector separates selected potential bioagent particles from the air, water, soil, or other substance that is being collected.
  • a sample preparation system prepares a sample of the selected potential bioagent particles. The sample is analyzed by a system for detecting said bioagents.
  • One embodiment includes a wash assay sample preparation system for preparing a sample of the selected potential bioagent particles.
  • the wash assay sample preparation system is operatively connected to the collector and prepares the sample from the air, water, soil, or other substance gathered by the collector.
  • the wash assay sample preparation system includes optically-encoded beads, a number of reagents, a washing buffer, and a detector for detecting any bioagents in the sample.
  • Another embodiment includes a no-wash assay sample preparation system for preparing a sample of the selected potential bioagent particles.
  • the no-wash assay sample preparation system is operatively connected to the collector for preparing the sample from the air, water, soil, or other substance gathered by the collector.
  • the no-wash assay sample preparation system includes optically-encoded beads, a number of reagents, and a detector for detecting any bioagents in the sample.
  • Another embodiment of the present invention provides an apparatus for sampling air and collecting sample particles of a predetermined particle size range from the air for autonomous monitoring air, water, soil, or other substance for bioagents.
  • a low pass section has an opening for gathering said air.
  • a prescreen unit is positioned in the opening that prevents large particles from blocking the opening.
  • FIG. 1 is a block diagram illustrating an embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 2 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 3 is a block diagram illustrating a specific embodiment of the invention designated as an AUTONOMOUS PATHOGEN DETECTION SYSTEM (APDS).
  • APDS AUTONOMOUS PATHOGEN DETECTION SYSTEM
  • FIGS. 4A and 4B are illustrations that show the aerosol collection system.
  • FIGS. 5A and 5B are illustrations that show the cap section limiting the larger particulate size range entering the collector.
  • FIG. 6 is an illustration that shows the virtual impactor section.
  • FIG. 7 shows the multistage, wetted-wall cyclone collector section.
  • FIGS. 8A, 8B , and 8 C show details of a specific embodiment of the aerosol collection system.
  • FIG. 9 is an illustration that shows another embodiment of the aerosol collection system.
  • FIG. 10 illustrates a system for sample preparation and detection.
  • FIGS. 11, 12 , and 13 illustrate the liquid-array based multiplex immunoassay detection system.
  • FIG. 14 is a block diagram illustrating the multiplex amplification and detection system.
  • FIG. 15 illustrates one specific embodiment of the in-line nucleic acid amplification and detection system.
  • FIG. 16 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 17 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 18 illustrates another embodiment of the present invention.
  • the autonomous pathogen detection system is designated generally by the reference numeral 100 .
  • the autonomous pathogen detection system 100 provides collection 101 , sample preparation 103 , and detection 105 .
  • the collection 101 includes gathering air, water, soil or other substance to provide an air sample, water sample, soil sample or a sample of other substances.
  • sample preparation 103 provides an automated sample, an immunoassay sample, and/or a nucleic acid assay sample.
  • sample preparation 103 the sample may be concentrated, purified, lysed, pulverized or otherwise made to have smaller particulates, mixed, and/or amplified.
  • the sample is transferred as shown by arrow 104 for detection.
  • the detection is by a multiplex immunoassay detector.
  • the detection is by a multiplex PCR detector. The detection may also be performed in the same location as the sample preparation, in which case the transfer arrow 104 is not required.
  • the autonomous pathogen detection system 100 provides an apparatus and method for monitoring air, water, soil, or other substance for particles containing bioagents.
  • the autonomous pathogen detection system 100 comprises a collector for gathering the air, water, soil, or other substance being monitored; sample preparation system for preparing a sample from the air, water, soil, or other substance gathered by the collector; and a detector for detecting any bioagents in the sample.
  • the collector is an aerosol collector. In other embodiments the collector gathers water, soil, or other substances.
  • the collector in one embodiment includes separator system for separating the particles of interest from other particles. The particles of interest are of a predetermined size range.
  • the collector is an aerosol collector that collects air and includes a system for separating the air into a bypass air flow that does not contain the particles of a predetermined particle size range and a product air flow that does contain the sample particles of a predetermined particle size range.
  • a wetted-wall cyclone collector receives the product air flow and traps and concentrates the particles of a predetermined particle size range in a liquid.
  • the sample preparation system is automated. In one embodiment the sample preparation system provides an immunoassay sample. In another embodiment the sample preparation system provides a nucleic acid assay sample. In another embodiment the sample preparation system includes concentration of the air, water, soil, or other substance. In another embodiment the sample preparation system includes purification of the air, water, soil, or other substance. In another embodiment the sample preparation system includes lysis of the air, water, soil, or other substance. In another embodiment the sample preparation system includes mixing of the air, water, soil, or other substance. In another embodiment the sample preparation system includes amplification.
  • the detector is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 100 , the detector is a multiplex PCR detector.
  • the primary focus of the autonomous pathogen detection system 100 is the protection of civilians from terrorist attacks; however, the system also has a role in protecting military personnel from biological warfare attacks.
  • the autonomous pathogen detection system 100 also has uses in medical facilities and research and development facilities.
  • the autonomous pathogen detection system 100 has uses in medical monitoring. There are a variety of medical applications where monitoring for biological pathogens would be useful. A good example of this is monitoring in hospitals and clinics for highly infectious agents such as tuberculosis or nosocomial diseases that can threaten the well being of patients and health care professionals.
  • the autonomous pathogen detection system 100 also has uses in environmental monitoring, that is, any application that would benefit from environmental monitoring of biological species.
  • One example is continuous aerosol monitoring of bacterial and other pathogens that could affect the health of livestock (such as the recent hoof and mouth disease outbreak).
  • Another example is continuous aerosol monitoring of viruses that could affect the health of large portions of the population (such as the recent SARS outbreak).
  • FIG. 2 another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention is illustrated by a block diagram.
  • This embodiment of the autonomous pathogen detection system is designated generally by the reference numeral 200 .
  • the autonomous pathogen detection system 200 provides collection 201 , sample preparation 203 , detection 205 , and confirmation 207 .
  • the collection 201 includes gathering air, water, soil or other substance to provide an air sample, water sample, soil sample or a sample of other substances.
  • sample preparation 203 provides an automated sample, an immunoassay sample, and/or a nucleic acid assay sample.
  • the sample may be concentrated, purified, lysed, pulverized or otherwise made to have smaller particulates, mixed, and/or amplified.
  • the sample is transferred as illustrated by arrow 204 for detection.
  • the detection is by a multiplex immunoassay detector.
  • the detection is by a multiplex PCR detector.
  • the system for confirmation of a bioagent in the sample is a multiplex immunoassay detector.
  • the system for confirmation of a bioagent in the sample is a multiplex PCR detector.
  • the system for confirmation of a bioagent in the sample is a real-time PCR detector. The detection may also be performed in the same location as the sample preparation, in which case the transfer arrows 204 and/or 206 are not required.
  • the autonomous pathogen detection system 200 provides an apparatus and method for monitoring air, water, soil, or other substance for particles containing bioagents.
  • the autonomous pathogen detection system 200 comprises a collector for gathering the air, water, soil, or other substance being monitored; sample preparation system for preparing a sample from the air, water, soil, or other substance gathered by the collector; a detector for detecting a bioagents in the sample; and a system for confirmation of a bioagent in the sample.
  • the collector is an aerosol collector. In other embodiments the collector gathers water, soil, or other substances.
  • the collector in one embodiment includes separator system for separating the particles of interest from other particles. The particles of interest are of a predetermined size range.
  • the collector is an aerosol collector that collects air and includes system for separating the air into a bypass air flow that does not contain the particles of a predetermined particle size range and a product air flow that does contain the sample particles of a predetermined particle size range.
  • a wetted-wall cyclone collector receives the product air flow and traps and concentrates the particles of a predetermined particle size range in a liquid.
  • the sample preparation system is automated. In one embodiment the sample preparation system provides an immunoassay sample. In another embodiment the sample preparation system provides a nucleic acid assay sample. In another embodiment the sample preparation system includes concentration of the air, water, soil, or other substance. In another embodiment the sample preparation system includes purification of the air, water, soil, or other substance. In another embodiment the sample preparation system includes lysis of the air, water, soil, or other substance. In another embodiment the sample preparation system includes mixing of the air, water, soil, or other substance. In another embodiment the sample preparation system includes amplification of the sample.
  • the detector 205 is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 200 , the detector 205 is a multiplex PCR detector.
  • the system 207 for confirmation of a bioagent in the sample is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 200 , the system 207 for confirmation of a bioagent in the sample is a multiplex PCR detector. In one embodiment of the autonomous pathogen detection system 200 , the system 207 for confirmation of a bioagent in the sample is a real-time PCR detector.
  • the APDS is designated generally by the reference numeral 300 .
  • the APDS 300 integrates a flow cytometer and PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins.
  • the APDS 300 is designed for locations where it continuously monitors air samples and automatically reports the presence of specific biological agents. Plague and anthrax are two of the pathogens the APDS 300 identifies, along with a host of others.
  • the APDS 300 includes the potential to measure up to 100 different agents and controls in a single sample.
  • the APDS 300 provides a stand-alone pathogen detection system capable of rapid, continuous, low cost environmental monitoring of multiple airborne biological threat agents.
  • the system 300 provides a “Detect to Protect/Warn” system with a number of key properties.
  • the system 300 is capable of detecting pathogens within a 1-2 hour time window, allowing for enough time to respond to an event.
  • the system 300 is extremely low cost to maintain, since continuous monitoring is essential for many applications.
  • the system 300 has sufficient sensitivity to cover a broad geographical area (limiting the necessary number of sensors) and has sufficient selectivity to virtually eliminate false positives.
  • An orthogonal detection section combines antibody-based and nucleic acid-based assays and reduces false positives to a very low level.
  • Antibody assays allow the detector to respond to all types of bioagents, including those without nucleic acids such as protein toxins.
  • Nucleic acid assays allow much more sensitive detection, reducing the number of sensors needed to protect a given area.
  • the fully autonomous aerosol collection and sample preparation capabilities limit maintenance requirements and makes integration into a central security or monitoring network possible.
  • a block diagram illustrates the APDS 300 .
  • an aerosol collector system continuously samples the air and traps particles in a swirling liquid solution. Particles of a given size distribution are selected by varying the flow rate across a virtual impactor unit.
  • the in-line sample preparation system provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performs multiplex detection using a Luminex flow cytometer.
  • a collected sample is mixed with optically encoded microbeads.
  • Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead.
  • Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • PCR amplification and detection of nucleic acids confirms the presence of the bioagent.
  • An archived sample is mixed with the TaqMan real-time PCR reagent, and then introduced by a SIA system into a flow-through polymerase chain reaction (PCR) system.
  • PCR polymerase chain reaction
  • Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the TaqMan probes.
  • a central computer uses a simple serial based LabVIEW control system to control all instrument functions.
  • a software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • the APDS 300 is integrated into a self-contained “ATM” style chassis. All fluids and reagents are contained in the instrument.
  • the ADPS 300 includes the following subsystems: Aerosol Collection 301 , In-Line Sample Preparation 302 , Detection—Liquid-Array Based Multiplex Immunoassay Detection and/or Nucleic Assays Detection 303 , Confirmation—In-Line Nucleic Acid Amplification and Detection 304 , and Integrated Remote Control and Feedback 305 .
  • Aerosol Collection 301 Aerosol Collection 301
  • In-Line Sample Preparation 302 Detection—Liquid-Array Based Multiplex Immunoassay Detection and/or Nucleic Assays Detection 303
  • Confirmation In-Line Nucleic Acid Amplification and Detection 304
  • Integrated Remote Control and Feedback 305 Integrated Remote Control and Feedback 305 .
  • the first stage of the APADS 300 is “aerosol collection” that provides collection of airborne particles that could contain targeted bioagents. Aerosol release of bioagents is considered one of the possible scenarios of a terrorist organization.
  • One of the methods of rapidly exposing a large population to a biowarfare agent is through use of an aerosol (witness the effect of the recent, relatively small-scale anthrax mailroom releases).
  • the aerosol collection system 301 continuously samples the air and traps particles in a swirling liquid solution. Particles of a given size distribution are selected by varying the flow rate across a virtual impactor unit.
  • the aerosol collection system 301 is a multi-stage aerosol collector that utilizes a low pass aerosol section and a virtual impactor preconcentration that delivers the particles of interest to a wetted wall cyclone collector.
  • the virtual impactor preferentially captures particles 1-10 micrometer (micron) which is the size of particles most likely to be captured in the human lung.
  • the particles are collected in a fluid, making downstream processing much easier.
  • the aerosol collection system provides improved sensitivity and reduced collection times.
  • An on-board computer controls air flow rates and the size range of particles collected.
  • a very high volume flow of aerosol particles is drawn into an annular slot 401 A formed in a cap 402 A that is designed to preferentially allow the passage of particles smaller than a pre-set size.
  • the pre-set size can be selected as desired.
  • a very high volume flow of aerosol particles (e.g., up to 3313 Lpm) can be drawn into the annular slot 401 A formed in the cap 402 A that is designed to preferentially allow the passage of particles smaller than 10 microns.
  • the accepted particles continue on into a dichotomous virtual impaction section 403 A that preferentially returns the aerosol particles smaller than 1-micron back into the environment.
  • the remaining particles, (1-10 microns) are known as the product flow.
  • the product flow continues into the next section.
  • a high volume flow of aerosol particles is drawn into the annular slot 401 A formed in the cap 402 A.
  • the annular slot 401 A is designed to limit the upper or larger particulate size range as they enter the collector.
  • the cap 402 A is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flow stream (in this case air) will not follow the streamlines exactly due to their inertia. If the curvature of a streamline is sufficiently large and the mass of the particulate is correspondingly high, the particle deviates far enough from the streamline to impact with a surface. The particles are drawn into the annular slot 401 A and directed into the transition section 409 A.
  • FIGS. 4B and 5B another embodiment of an aerosol collection system is illustrated.
  • This embodiment is designated generally by the reverence numeral 300 B.
  • a very high volume flow of aerosol particles 405 B is drawn into an annular slot 401 B formed in a cap 402 B that is designed to only allow the passage of particles smaller than a pre-set size.
  • the pre-set size can be selected as desired.
  • a very high volume flow of aerosol particles 405 B can be drawn into the annular slot 401 B formed in the cap 402 B that is designed to only allow the passage of particles smaller than 10 microns.
  • a pre-screen 404 B prevents large particles from blocking small flow paths such as the flow path 401 B.
  • the accepted particles continue on into a dichotomous virtual impaction section 403 B that returns all the aerosol particles smaller than 1-micron back into the environment.
  • the remaining particles, (1-10 microns) are known as the product flow.
  • the product flow continues into the next section.
  • the pre-screen unit 404 B in one embodiment is a grill positioned in the opening 401 B.
  • the pre-screen unit in another embodiment is a screen positioned in the opening 401 B.
  • the opening 401 B in the low pass section is an annular slot and the pre-screen unit 404 B is an annular screen positioned in the opening 401 B.
  • the pre-screen 404 B is located inside the cap 402 B covering the top of the inner cylinder shown as 409 B in FIGS. 5A and 5B .
  • a high volume flow of aerosol particles 405 B is drawn into the annular slot 401 B formed in the cap 402 B.
  • the annular slot 401 B is designed to limit the upper or larger particulate size range as they enter the collector.
  • the embodiment 300 B is particularly suited for operating in dirty environments such as subway stations.
  • a prescreen unit 404 B is positioned at the entrance to the annular slot 401 B to prevent large particles from blocking the small flow paths of the virtual impactor.
  • the cap 402 B is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flow stream (in this case air) will not follow the streamlines exactly due to their inertia. If the curvature of a streamline is sufficiently large and the mass of the particulate is correspondingly high, the particle deviates far enough from the streamline to impact with a surface. The particles are drawn through the pre-screen 404 B into the annular slot 401 B and directed into the transition section 409 B.
  • nightly clean-in-place protocols are implemented to keep the walls of the wetted-wall-cyclone clean using reagents such as dilute bleach and surfactant solutions.
  • the optical bubble counter is cleaned periodically with a pipe-cleaner, catheter, or other such tool.
  • the APDS 300 A has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time.
  • the system is entirely self-contained requiring only a 110 V ac power connection.
  • the on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • the APDS 300 A is useful for most environmental sampling. It is particularly useful with biological material collection, but can be used for collecting any airborne matter.
  • the APDS 300 A can be used to sample air quality in public buildings such as convention centers and sports arenas, for sampling in food processing facilities, sampling animal pens (such as poultry houses), or for use in monitoring orchards or agricultural areas for the presence of pollens or pesticides. Because of its relatively compact size and weight it can be used to sample in confined spaces such as found in aircraft or subway systems.
  • the separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle and collection probe.
  • the key is particulate larger than the cut size become concentrated in the minor flow.
  • the concentration factor is the ratio of the total flow to the minor flow. (If the minor flow is 25% of the total flow, then the concentration factor is 4.)
  • the aerosol passes through an acceleration nozzle 601 .
  • the acceleration nozzle 601 has a diameter D 0 .
  • the aerosol is directed toward a collection probe 602 .
  • the collection probe has a diameter D 1 .
  • a major portion of the flow 603 is diverted 90° away.
  • the minor or “product” flow 604 continues axially.
  • the flow forms streamlines 605 .
  • Small particles with low inertia 606 follow the flow streamlines and are carried away radially with the major flow 603 .
  • Large particles with greater inertia 607 deviate from the flowlines but they continue moving axially in their forward path down the collection probe 602 with the minor or “product” flow 604 .
  • the separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle D 0 and collection probe D 1 .
  • the key is particulate larger than the cut size become concentrated in the minor flow.
  • the concentration factor is the ratio of the total flow to the minor flow.
  • the particles, (1-10 microns) known as the product flow are directed into a multi-stage, wetted-wall cyclone collection section. In this stage of the sampling system the product particles are trapped and concentrated into a liquid, typically water, in a volume between 2 and 7 cc.
  • An on-board computer monitors and controls the flow of air through the system using built in hot wire anemometers, as well as controlling the liquid level in the cyclone. At a selected time the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the sample via an external liquid sample port.
  • the product flow particles enter a stainless steel funnel section into the input of a multistage, wetted-wall cyclone collector section 700 .
  • the system includes a cyclone collector 701 , peristaltic pump 707 , an air pump 704 , a vent 706 , wash 705 , 8 liter DD-H2O (double deionized water) reservoir 702 , and 1 liter bleach reservoir 703 .
  • the reservoirs 702 and 703 are provided as external tanks outside of the front panel interface 708 .
  • the multistage, wetted-wall cyclone collector section 700 directs the particles of interest to the sample preparation system 302 .
  • the on-board computer monitors and controls the flow of air through the system using built in hot wire anemometers that have been mounted in the two exhaust ports of the sampler.
  • the computer and control software also act to control the liquid level in the cyclone, and monitor all status indicators of the sampling system.
  • the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the collected liquid sample via an external sample port.
  • the system also has the capability to measure particle sizes in the background environment via a built in particle counter such as particle counter Biotest APC-1000, with four size ranges, and can store and display the results in real-time.
  • the system 300 is entirely self-contained requiring only a 110 vac power connection.
  • the on-board computer has high-speed communications capability allowing networking of multiple sampling systems to be remotely operated.
  • the computer has extra RS-232 or RS-485 serial ports that can be used to control other instrumentation.
  • the aerosol collection system 301 is designated “High Collection Rate Aerosol Sampling System” (HiCRASS).
  • HiCRASS comprises: Low Pass “Cap” 402 ; Transition Section 409 ; Virtual Impactor 403 ; Funnel Section 410 ; Multistage, Wetted-wall Cyclone Collector 700 ; Bypass Fan 412 ; and Control Computer 714 .
  • the HiCRASS system provides a very high volume flow of aerosol particles (e.g., up to 3313 Lpm) that are drawn into the annular slot 401 formed in the cap 402 that is designed to limit the upper or larger particulate size range as they enter the collector.
  • the annular slot 401 allows the passage of particles smaller than 10 microns.
  • the cap 402 is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flowstream (in this case air) will not follow the streamlines exactly due to their inertia.
  • the curvature of the streamline is sufficiently large and the mass of the particulate is correspondingly high that the particle deviates far enough from the streamline to impact with a surface.
  • the accepted particles continue around the corner and onto the dichotomous virtual impaction section 403 that returns substantially all the aerosol particles smaller than 1-micron back into the environment.
  • the virtual impactor 403 works as the aerosol passes through an accelerating nozzle 601 and is directed toward a collection probe 602 where a major portion of the flow 603 is diverted 90° away from it.
  • the flow forms streamlines 605 .
  • Small particles with low inertia 606 follow the flow streamlines and are carried away radially with the major flow 603 .
  • Large particles with greater inertia 607 deviate from the flowlines but they continue moving axially in their forward path down the collection probe 602 with the minor or “product” flow 604 .
  • the separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle D 0 and collection probe D 1 . Particulate larger than the cut size become concentrated in the minor flow.
  • the concentration factor is the ratio of the total flow to the minor flow. (If the minor flow is 25% of the total flow, then the concentration factor is 4).
  • the remaining particles (1-10 microns) now known as the product 604 flow down a stainless steel funnel section into the input of the multistage, wetted-wall cyclone collector section 700 .
  • the wetted-wall cyclone collector section 700 is a system that causes the product flow particles 604 to be collected by a liquid.
  • the wetted-wall cyclone collector section 700 operates by forcing the air stream tangentially into a cylinder causing the air stream to circulate around the inside of the cylinder. Particles in the air stream having sufficient inertia will collide with the interior wall where they are collected by the liquid that circulates along the interior wall.
  • the on-board computer 714 monitors and controls the flow of air through the system using built-in hot wire anemometers, as well as controlling the liquid level in the cyclone 700 . At a selected time the computer 714 will stop the flow of air and turn on a built-in peristaltic pump to deliver the sample via an external sample port. The on-board computer 714 monitors and controls the flow of air through the system using built in hot wire anemometers that have been mounted in the two exhaust ports of the sampler. The computer and control software also act to control the liquid level in the cyclone, and monitor all status indicators of the sampling system. At a selected time the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the collected liquid sample via an external sample port.
  • the system also has the capability to measure particle sizes in the sampling environment via a built in particle counter such as particle counter Biotest APC-1000, with four size ranges, and can store and display the results in real-time.
  • the system is entirely self-contained requiring only a 110 vac power connection.
  • the on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • This collection section system is designated generally by the reference numeral 900 .
  • the system 900 samples the air 901 and collects sample particles of a predetermined particle size range from the air.
  • the system 900 is particularly useful with the latest generation of Biological Warfare agent detection systems.
  • An air sampling system is a critical component in integrated biological warfare detection system.
  • the system 900 also has use in medical facilities and research and development facilities.
  • a low pass section 902 has an opening of a preselected size for gathering the air 901 but excluding particles larger than the sample particles.
  • the opening of a preselected size is an annular slot that only allows the passage of particles smaller than 10 microns.
  • the low pass section 902 produces a total air flow 903 that contains the sample particles of a predetermined particle size range.
  • the low pass section 902 allows a very high volume flow of air to be drawn through the preselected size opening. In one embodiment, the very high volume flow of air is 3313 Lpm or less.
  • An impactor section 904 is connected to the low pass section 902 and receives the total air flow 903 .
  • the impactor section 904 separating the total air flow 903 into a bypass air flow 905 that does not contain the sample particles and a product air flow 906 that does contain the sample particles.
  • An accelerating nozzle and a collection probe in the impactor section 904 diverts the bypass air flow 90° from the product air flow thereby separating the bypass air flow and the product air flow.
  • the bypass air flow and the product air flow separation is determined by the ratio of the bypass air flow and the product air flow.
  • the bypass air flow and the product air flow separation is determined by the physical dimensions of the accelerating nozzle and the collection probe.
  • the bypass air flow and the product air flow separation is determined by the ratio of the bypass air flow and the product air flow and the physical dimensions of the accelerating nozzle and the collection probe.
  • a wetted-wall cyclone collector section 907 is connected to the impactor section 904 .
  • the wetted-wall cyclone collector section 907 receives the product air flow 906 and traps the sample particles in a liquid.
  • the sample particles of a predetermined particle size range are concentrated in the liquid.
  • the wetted-wall cyclone collector section 907 traps and concentrates the sample particles into a liquid in a volume between 2 and 7 cc.
  • the liquid is water.
  • the system 900 is useful for most environmental sampling. It is particularly useful with biological material collection, but can be used for collecting any airborne matter.
  • the system 900 can be used to sample air quality in public buildings such as convention centers and sports arenas, for sampling in food processing facilities, sampling animal pens (such as poultry houses), or for use in monitoring orchards or agricultural areas for the presence of pollens or pesticides. Because of its relatively compact size and weight it can be used to sample in confined spaces such as found in aircraft or subway systems.
  • the in-line sample preparation module 302 moves the sample from the aerosol collection module 301 to appropriate modules within the APDS 300 and provides sample preparation.
  • the sample preparation module 302 prepares the sample (mixing, filtering, incubation, etc.) and delivers the sample reaction volume to the liquid-array based multiplex immunoassay detection system 303 .
  • the sample preparation module 302 prepares the sample (mixing, filtering, incubation, etc.) and delivers the sample reaction volume to the in-line nucleic acid detection system 304 .
  • Zone fluidics is the precisely controlled physical, chemical, and fluid-dynamic manipulation of zones of miscible and immiscible fluids in narrow bore conduits to accomplish sample conditioning and chemical analysis.
  • a zone is a volume region within a flow conduit containing at least one unique characteristic.
  • a unit operation in zone fluidics comprises of a set of fluid handling steps intended to contribute to the transformation of the sample into a detectable species or prepare it for manipulation in subsequent unit operations.
  • unit operations include sample filtering, dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting.
  • sample filtering dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting.
  • many of these steps are handled manually or in isolated pieces of equipment. Integration is scant at best, and there is a high degree of analyst involvement.
  • zone fluidics sample and reagent zones are subjected to these unit operations in a sequential manner being transported from one unit operation to the next under fluidic control.
  • Samples in zone fluidics are not limited to liquids. Rather, gases, and suspensions containing solids or cells are also included. Where solid samples are used, particles are limited to a size that ensures no blockages.
  • reagents are prepared and then coupled to the zone fluidics manifold.
  • the metering capability of the pump and mixing unit operations allow for reagents and standards to be prepared in situ. Reagents can therefore be presented to the zone fluidics manifold in an appropriately designed cartridge as ready-made, reagent concentrates, lyophilized, or crystalline form. Standards can be plumbed to the multi-position valve as discrete reservoirs providing the required range of concentrations. As for reagents though, standards can also be prepared in situ or diluted to cover a larger dynamic range.
  • the sample preparation module 302 uses a powerful, highly flexible technique called sequential injection analysis (SIA). Automation is achieved through the manipulation of small solution zones under conditions of controlled dispersion in narrow bore tubing. Zone fluidics makes use of a multi-position selection valve and a high precision, bi-directional pump to construct a stack of well-defined sample and reagent zones in a holding coil of narrow bore tubing. By appropriate manipulation of this zone stack, a wide range of sample handling unit operations can be accommodated. The pump is used to move the sample from one device to the next achieving the required sample manipulation in the process. Once a detectable species has been formed, the zone stack is transported to the immunoassay detector 303 and to the nucleic acid detector 304 .
  • SIA sequential injection analysis
  • FIGS. 10-13 Various embodiments of system for sample preparation and detection have been described in connection with FIGS. 10-13 .
  • Applicants will now describe additional embodiments of the immunoassay system of the present invention.
  • These embodiments of the immunoassay system can use either “wash assay” system or “no-wash assay” system.
  • the “wash assay” system and the “no-wash assay” system use optically-encoded beads.
  • the beads are kept in a small ( ⁇ 15 mL) stirred tank. Bead loss from agglomeration is reduced by using dispersing agents such as ethanol in the bead slurry. This reduces reagent cost.
  • the wash assay system embodiment uses a number of reagents in addition to the liquid sample.
  • the reagents include detector antibody, and fluorescent reporter (streptavidin-phycoerythrin).
  • a bed of beads is deposited on a filter then exposed to the sample, washing buffer, detector antibody, washing buffer, fluorescent reporter, washing buffer, and then the beads are released to the detector.
  • the bead filter performance in releasing beads is improved by implementing frequent clean-in-place protocols using reagents such as bleach for cleaning and morpholine propane sulfonic acid (MOPS) citrate buffer for reconditioning the filter. This extends the time between servicing the instrument and thus reduces operating cost.
  • MOPS morpholine propane sulfonic acid
  • the reagents are sequentially mixed but the embodiment does not include the filter or the wash steps. It has been shown that the wash assays are more sensitive and selective, providing better signal-to-noise ratios in response to bioagents.
  • the system 1400 comprises the following: Sample Collection 1401 , Sample Preparation 1402 , Multiplex Amplification PCR 1403 , and Multiplex, Liquid Array Based Detection of PCR Amplicons 1404 .
  • the first stage of the system 1400 is “sample collection 1401 ” that provides collection of particles that could contain targeted bioagents.
  • the sample collection 1401 gathers air, water, soil, or other substance being monitored.
  • the sample collection 1401 separates selected potential bioagent particles from the air, water, soil, or other substance.
  • sample preparation 1402 moves the sample from the sample collection to appropriate modules within the system 1400 and provides sample preparation.
  • the sample preparation 1402 prepares the sample (Lysis, Concentration, Purification, Mixing, etc.) and delivers the sample to “Multiplex Amplification PCR 1403 .”
  • One mode provides “Multiplex, Liquid Array Based Detection of PCR Amplicons 1404 .”
  • An example of a flow cytometric detection method for DNA samples is shown in U.S. patent application 2002/0155482 by Shanavaz Nasarabadi, Richard G. Langlois, and Kodumudi Venkateswaran published Oct. 24, 2002. The disclosure of U.S. patent application 2002/0155482 is incorporated herein by reference.
  • the system 1500 is capable of performing, singly or in combination, nucleic acid amplification, and nucleic acid detection functions.
  • the nucleic acid assay system 1500 includes a number of components including system for injecting/aspirating a sample, 1501 , system for adding PCR reagent 1502 , system for mixing sample and reagent 1503 , system for transport to PCR reactor 1504 , system for performing PCR amplification 1505 , system for transport of amplified sample from PCR reactor 1506 , system for detection of PCR amplicons 1507 , and system for decontamination and conditioning of all exposed conduits 1508 .
  • the system 1501 for injecting and or aspirating a sample provides injection and/or aspiration of the sample.
  • the injecting/aspirating system 1501 consists of a zone fluidics system.
  • the injecting/aspirating system 1501 consists of an FIA system.
  • the system 1501 for injecting and or aspirating a sample can be, for example, a injecting/aspirating device available under the trademark milliGATTM pump, Global FIA, Inc., Fox Island, Wash.
  • the system 1502 for adding PCR reagent to the sample is operatively connected to the system 1501 for injecting and or aspirating a sample.
  • the system 1502 for adding PCR reagent to the sample can be, for example, a unit for adding PCR reagent to the sample such as an injection or multi position selection valve, available from VICI, Houston, Tex.
  • the system 1503 for mixing the sample and the reagent is operatively connected to the system 1502 for adding PCR reagent to the sample.
  • the mixing system 1503 mixes the sample with a PCR reagent.
  • the PCR reagent includes primers.
  • the PCR reagent includes oligos.
  • the system 1503 for mixing the sample and the reagent can be, for example, a super serpentine reactor, available from Global FIA, Inc., Fox Island, Wash.
  • the system 1504 for transporting the sample and the reagent to a PCR reactor is operatively connected to the system 1503 for mixing the sample and the reagent.
  • the system 1504 for transporting the sample and the reagent to a PCR reactor consists of a fluidics system.
  • the system 1504 for transporting the sample and the reagent to a PCR reactor can be, for example, FEP tubing available from Cole-Parmer, Vernon Hills, Ill.
  • the system 1505 for performing PCR amplification is operatively connected to the system 1504 for transporting the sample and the reagent to a PCR reactor. This results in an amplified sample.
  • the PCR amplification system 1505 includes an embedded thermocouple calibration conduit.
  • PCR amplification devices are described in publications such as U.S. Pat. No. 5,589,136 for silicon-based sleeve devices for chemical reactions, assigned to the Regents of the University of California, inventors: M. Allen Northrup, Raymond P. Mariella, Jr., Anthony V. Carrano, and Joseph W. Balch, patented Dec.
  • the system 1506 for transporting the amplified sample from the PCR reactor is operatively connected to the system 1205 for performing PCR amplification.
  • the system 1506 for transporting the amplified sample from the PCR reactor can be, for example, FEP tubing available from Cole-Parmer, Vernon Hills, Ill.
  • the system 1507 for detection of PCR amplicons is operatively connected to the system 1506 for transporting the amplified sample from the PCR reactor.
  • the system 1507 for detection of PCR amplicons can be, for example, a detection system described in publications and products produced by Cepheid and Baltimore-based Environmental Technologies Group, Inc. (ETG), a part of London-based Smiths Aerospace.
  • Conduits are included within the system 1501 for injecting and or aspirating a sample, system 1502 for adding PCR reagent to the sample, system 1503 for mixing the sample and the reagent, system 1504 for transporting the sample and the reagent to a PCR reactor, system 1505 for performing PCR amplification, system 1506 for transporting the amplified sample from the PCR reactor, and system 1507 for detection of PCR amplicons.
  • a system 1508 for decontamination and conditioning the conduits is directly connected to the system 1507 for detection of PCR amplicons.
  • the system 1508 for decontamination and conditioning the conduits is operatively connected to the system 1501 for injecting and or aspirating a sample, system 1502 for adding PCR reagent to the sample, system 1503 for mixing the sample and the reagent, system 1504 for transporting the sample and the reagent to a PCR reactor, system 1505 for performing PCR amplification, system 1506 for transporting the amplified sample from the PCR reactor, and system 1507 for detection of PCR amplicons.
  • the decontamination and conditioning of all exposed conduits can be, for example, be performed by using a decontaminant, such as bleach, which is pumped through the exposed conduits and then washed from the system with a suitable wash solution.
  • FIG. 16 a block diagram illustrates another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • This embodiment of an autonomous pathogen detection system is designated generally by the reference numeral 1600 .
  • the autonomous pathogen detection system 1600 provides water sample collection 1601 , sample preparation 1602 , and detection 1603 and 1604 .
  • a water sample collection unit 1601 continuously samples a water source.
  • Water sampling systems are known in the art.
  • a water sampling system is shown in U.S. Pat. No. 6,306,350 issued Oct. 23, 2001 titled “Water Sampling Method and Apparatus With Analyte Integration.” The disclosure of U.S. Pat. No. 6,306,350 is incorporated herein by reference.
  • the in-line sample preparation unit 1602 concentrates the sample in a swirling buffer solution. Particles of a given size distribution are selected by varying the flow rate across a separator unit.
  • the in-line sample preparation system 1602 provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performing multiplex detection using a Luminex flow cytometer.
  • a collected sample is mixed with optically encoded microbeads.
  • Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead.
  • Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • PCR nucleic acid
  • a central computer uses a simple serial based LabVIEW control system to control all instrument functions.
  • a software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • the first stage of the system 1600 is “water sample collection 1601 ” that provides collection of particles from a source of water that could contain bioagents.
  • the water sample collection system 1601 and in-line sample preparation 1602 provide preconcentration and delivery of the particles of interest to a wetted wall cyclone collector.
  • the separator system captures particles of interest.
  • the particles are collected in a fluid, making downstream processing much easier.
  • An on board computer controls water flow rates and the size range of particles collected.
  • a particle counter provides real-time feedback on the size and quantity of particles collected.
  • Particles are drawn into the system that is designed to only allow the collection of particles of a pre-set size.
  • the pre-set size can be selected as desired.
  • the system is designed to only collect particles that are desired.
  • the accepted particles continue on into a separator section that returns all the particles that are not of the desired size back into the environment.
  • the remaining particles are known as the product flow.
  • the product flow continues into the detection sections.
  • the system 1600 has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time.
  • the system is entirely self-contained requiring only a power connection.
  • the on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • the 1600 is useful for many application of water sampling.
  • the system 1600 can be used to sample water quality in public buildings, for sampling in food processing facilities, for use in monitoring agricultural areas for the presence of pollens or pesticides and other water sampling uses.
  • FIG. 17 a block diagram illustrates another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • This embodiment of an autonomous pathogen detection system is designated generally by the reference numeral 1700 .
  • the autonomous pathogen detection system 1700 provides soil sample collection 1701 , sample preparation 1702 , and detection 1703 and 1704 .
  • a soil sample collection unit 1701 continuously samples a soil source.
  • Soil sampling systems are known in the art.
  • a soil sampling system is shown in U.S. Pat. No. 6,363,803 titled “Vehicle Mounted Soil Sampler,” invented by Elmer Hubers, patented Apr. 2, 2002.
  • the disclosure of U.S. Pat. No. 6,363,803 is incorporated herein by reference.
  • the in-line sample preparation unit 1702 concentrates the sample in a swirling buffer solution. Particles of a given size distribution are selected by varying the flow rate across a separator unit.
  • the in-line sample preparation system 1702 provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performing multiplex detection using a Luminex flow cytometer.
  • a collected sample is mixed with optically encoded microbeads.
  • Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead.
  • Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • PCR nucleic acid
  • a central computer uses a simple serial based LabVIEW control system to control all instrument functions.
  • a software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • the first stage of the system 1700 is “soil sample collection 1701 ” that provides collection of particles from a source of soil that could contain bioagents.
  • the soil sample collection system 1701 and in-line sample preparation 1702 provide preconcentration and delivery of the particles of interest to a wetted wall cyclone collector.
  • the separator system captures particles of interest.
  • the particles are collected in a fluid, making downstream processing much easier.
  • An on board computer controls soil flow rates and the size range of particles collected.
  • a particle counter provides real-time feedback on the size and quantity of particles collected.
  • Particles are drawn into the system that is designed to only allow the collection of particles of a pre-set size.
  • the pre-set size can be selected as desired.
  • the system is designed to only collect particles that are desired.
  • the accepted particles continue on into a separator section that returns all the particles that are not of the desired size back into the environment.
  • the remaining particles are known as the product flow.
  • the product flow continues into the detection sections.
  • the system 1700 has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time.
  • the system is entirely self-contained requiring only a power connection.
  • the on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • the 1700 is useful for many application of soil sampling.
  • the system 1700 can be used to sample soil quality in monitoring agricultural areas for the presence of pollens or pesticides and other soil sampling uses.
  • the system 1800 is capable of performing, singly or in combination, liquid-array based multiplex immunoassay detection and/or in-line nucleic acid amplification and detection.
  • the aerosol collector system 1801 samples the air, particles of a given size distribution are trapped in a liquid, and a sample of interest is prepared.
  • the next step is detection of any pathogens in the sample particles. This is accomplished by a liquid-array based multiplex immunoassay detection system 1802 and an in-line nucleic acid amplification and detection system 1803 .
  • the liquid-array based immunoassay detection system 1802 measures multiple pathogen targets in the sample.
  • the immunoassay system 1802 can use either “wash assay” system or “no-wash assay” system.
  • the “wash assay” system and the “no-wash assay” system use optically-encoded beads.
  • the beads are kept in a small ( ⁇ 15 mL) stirred tank. Bead loss from agglomeration is reduced by using dispersing agents such as ethanol in the bead slurry. This reduces reagent cost.
  • the wash assay system embodiment uses a number of reagents in addition to the liquid sample.
  • the reagents include detector antibody, and fluorescent reporter (streptavidin-phycoerythrin).
  • a bed of beads is deposited on a filter then exposed to the sample, washing buffer, detector antibody, washing buffer, fluorescent reporter, washing buffer, and then the beads are released to the detector.
  • the bead filter performance in releasing beads is improved by implementing frequent clean-in-place protocols using reagents such as bleach for cleaning and morpholine propane sulfonic acid (MOPS) citrate buffer for reconditioning the filter. This extends the time between servicing the instrument and thus reduces operating cost.
  • MOPS morpholine propane sulfonic acid
  • the reagents are sequentially mixed but the embodiment does not include the filter or the wash steps. It has been shown that the wash assays are more sensitive and selective, providing better signal-to-noise ratios in response to bioagents.
  • the PCR (nucleic acid) amplification and detection system 1803 confirms the presence of any bioagent.
  • An archived sample is mixed with the TaqMan reagent, and then introduced by a system into a flow through polymerase chain reaction (PCR) system.
  • PCR polymerase chain reaction
  • Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the TaqMan probes.
  • the PCR assays for confirming immunoassay positives are implemented using real-time PCR and the TaqMan process. Both FAM and TAMRA dyes are used as TaqMan reporters and TAMRA and BHQ (Black Hole Quencher) dyes are used as TaqMan quenchers.
  • FAM-BHQ is used for the bioagent probe and TAMRA-BHQ for an internal control probe. This allows an internal control to be used on a two-color detector. Internal controls are critical in PCR due to the delicacy of the reaction; otherwise, negative results are not definitive.
  • two color excitation is used to give strong signals for duplexed TaqMan PCR (agent plus internal control).
  • the PCR reagents for TaqMan PCR are stored on the system together as MasterMix (enzyme, buffer, dNTPs) mixed with primers and probes.
  • MasterMix enzyme, buffer, dNTPs
  • extraction of DNA onto microfabricated silica pillars is used as a means of purifying DNA from PCR inhibitors.
  • the nucleic acid assay system 1803 includes a number of components including system for injecting/aspirating a sample, system for adding PCR reagent, system for mixing sample and reagent, system for transport to PCR reactor, system for performing PCR amplification, system for transport of amplified sample from PCR reactor for detection of PCR amplicons.
  • a central computer 1805 uses a simple serial based LabVIEW control system to control all instrument functions.
  • a software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • the in-line nucleic acid amplification and detection system provides nucleic acid assay methods.
  • the methods include a number of steps.
  • One step consists of automatically injecting and or aspirating a sample.
  • Another step consists of automatically adding PCR reagent to the sample.
  • Another step consists of automatically mixing the sample and the reagent.
  • Another step consists of automatically transporting the sample and the reagent to a PCR reactor.
  • the PCR reactor consists of a fluidics system.
  • Another step consists of automatically performing PCR amplification resulting in an amplified sample.
  • Another step consists of automatically transporting the amplified sample from the PCR reactor.
  • Another step consists of automatically detecting PCR amplicons.
  • the method is performed in a nucleic acid assay system and the nucleic acid assay system is decontaminated and conditioned before a new sample is analyzed.
  • the system includes both real-time and post-PCR detection.
  • the system is ideal for monitoring type systems, such as those currently being developed to detect terrorist releases of aerosolized bioagents.
  • On-site detection systems for infectious diseases under development will need to incorporate sample preparation and analysis functions.
  • the system allows relatively unskilled personnel, such as early responders, to perform real-time field or point-of-care nucleic acid assays.
  • the confirmation of bioagent(s) in the sample is provided by a multiplex immunoassay detector, a multiplex PCR detector, and a real-time PCR detector.
  • the present invention provides an Autonomous Pathogen Detection System (APDS) for monitoring the environment to protect the public from the release of hazardous biological agents.
  • APDS Autonomous Pathogen Detection System
  • the Autonomous Pathogen Detection System is a countermeasure to bioterrorism, one of the most serious threats to the safety of United States citizens, citizens of other countries, and the military.
  • the APDS program was initiated to fill the requirement of a distributed environmental monitoring system for civilian applications. Multiplexed assays are used to reduce reagent costs, making long term monitoring operations possible (e.g., U.S. Postal Service mail screening).
  • a unique, orthogonal detection approach that combines antibody-based and nucleic acid-based assays reduces false positives to a very low level.
  • Antibody assays allow the detector to respond to all types of bioagents, including those without nucleic acids such as protein toxins.
  • Nucleic acid assays allow much more sensitive detection, reducing the number of sensors needed to protect a given area.
  • the fully autonomous aerosol collection and sample preparation capabilities limit maintenance requirements and makes integration into a central security or monitoring network possible.
  • the primary needs describe above are directed to protection of civilians from terrorist attacks.
  • the system also has uses in protecting military personnel from biological warfare attacks.
  • the military continues to evaluate options to their current biowarfare detection systems and the system meets many of the needs of the military.

Abstract

An autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents. A collector gathers a quantity of the air, water, soil, or other substance being monitored. A sample preparation system prepares a sample of the selected potential bioagent particles. The sample is analyzed by a system for detecting said bioagents.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation-in-Part of U.S. patent application Ser. No. 10/643797 filed Aug. 19, 2003 and titled, “System for Autonomous Monitoring of Bioagents” which claims the benefit of U.S. Provisional Patent Application No. 60/406159 filed Aug. 26, 2002 titled “System for Autonomous Monitoring of Bioagents.” U.S. patent application Ser. No. 10/643797 filed Aug. 19, 2003 and U.S. Provisional Patent Application No. 60/406159 filed Aug. 26, 2002, both titled, “System for Autonomous Monitoring of Bioagents,” are incorporated herein by this reference.
  • The United States Government has rights in this invention pursuant to Contract No. W-7405-ENG-48 between the United States Department of Energy and the University of California for the operation of Lawrence Livermore National Laboratory.
  • BACKGROUND
  • 1. Field of Endeavor
  • The present invention relates to bioagents and more particularly to monitoring bioagents.
  • 2. State of Technology
  • There exists a critical need to develop distributed biothreat agent sensor networks that can operate in civilian applications. To operate in “Detect to Protect/Warn” type detection architectures, these platforms need to have several key properties. They need to be capable of detecting pathogens within a 1-2 hour time window, allowing for enough time to respond to an event. They need to be extremely low cost to maintain, since continuous monitoring is essential for many applications. These platforms need to have sufficient sensitivity to cover a broad geographical area (limiting the necessary number of sensors) and have sufficient selectivity to virtually eliminate false positives. Currently available bioweapons detection systems are designed primarily for military use on the battlefield. These systems are often expensive to deploy and ultimately unsuited for civilian protection.
  • In an article titled, “U.S. Is Deploying a Monitor System for Germ Attacks,” by Judith Miller in The New York Times on Jan. 22, 2003, it was reported, “To help protect against the threat of bioterrorism, the Bush administration on Wednesday will start deploying a national system of environmental monitors that is intended to tell within 24 hours whether anthrax, smallpox and other deadly germs have been released into the air, senior administration officials said today. The system uses advanced data analysis that officials said had been quietly adapted since the September 11 attacks and tested over the past nine months. It will adapt many of the Environmental Protection Agency's 3,000 air quality monitoring stations throughout the country to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill . . . . The new environmental surveillance system uses monitoring technology and methods developed in part by the Department of Energy's national laboratories. Samples of DNA are analyzed using polymerase chain reaction techniques, which examine the genetic signatures of the organisms in a sample, and make rapid and accurate evaluations of that organism . . . . Officials who helped develop the system said that tests performed at Dugway Proving Ground in Utah and national laboratories showed that the system would almost certainly detect the deliberate release of several of the most dangerous pathogens. ‘Obviously, the larger the release, the greater the probability that the agent will be detected,’ an official said. ‘But given the coverage provided by the E.P.A. system, even a small release, depending on which way the wind was blowing and other meteorological conditions, is likely to be picked up.’”
  • In an article titled, “Biodetectors Evolving, Monitoring U.S. Cities,” by Sally Cole in the May 2003 issue of Homeland Security Solutions, it was reported, “The anthrax letter attacks of 2001, and subsequent deaths of five people, brought home the reality of bioterrorism to Americans and provided a wake-up call for the U.S. government about the need for a method to detect and mitigate the impact of any such future attacks. Long before the anthrax letter attacks, scientists at two of the U.S. Department of Energy's national laboratories, Lawrence Livermore National Laboratory (LLNL) and Los Alamos National Laboratory (LANL), were busy pioneering a “biodetector” akin to a smoke detector to rapidly detect the criminal use of biological agents. This technology is now expected to play a large role in the U.S. government's recently unveiled homeland security counter-terrorism initiative, Bio-Watch, which is designed to detect airborne bioterrorist attacks on major U.S. cities within hours. Announced back in January, Bio-Watch is a multi-faceted, multi-agency program that involves the U.S. Department of Energy, the Environmental Protection Agency (EPA), and the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC). Many of the EPA's 3,000 air-quality monitoring stations throughout the country are being adapted with biodetectors to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill, according to the EPA. The nationwide network of environmental monitors and biodetectors, which reportedly will eventually monitor more than 120 U.S. cities, is expected to detect and report a biological attack within 24 hours. Citing security reasons, the EPA declined to disclose further details about the program at this time . . . . The Autonomous Pathogen Detection System (APDS) is a file-cabinet-sized machine that sucks in air, runs tests, and reports the results itself. APDS integrates a flow cytometer and real-time PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins. The system is designed for fixed locations, says Langlois, where it continuously monitors air samples and automatically reports the presence of specific biological agents. APDS is targeted for domestic applications in which the public is at high risk of exposure to covert releases of bioagents—subway systems, transportation terminals, large office complexes, and convention centers . . . . APDS provides the ability to measure up to 100 different agents and controls in a single sample,’ Langlois says. ‘It's being used in public buildings right now.’ The latest evolution of the biodetector, APDS-II, uses bead-capture immunoassays and a compact flow cytometer for the simultaneous identification of multiple biological simulants. Laboratory tests have demonstrated the fully autonomous operation of APDS-II for as long as 24 hours.”
  • SUMMARY
  • Features and advantages of the present invention will become apparent from the following description. Applicants are providing this description, which includes drawings and examples of specific embodiments, to give a broad representation of the invention. Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this description and by practice of the invention. The scope of the invention is not intended to be limited to the particular forms disclosed and the invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims. (0008) The present invention provides an autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents. A collector gathers a quantity of the air, water, soil, or other substance being monitored. The collector separates selected potential bioagent particles from the air, water, soil, or other substance that is being collected. A sample preparation system prepares a sample of the selected potential bioagent particles. The sample is analyzed by a system for detecting said bioagents.
  • One embodiment includes a wash assay sample preparation system for preparing a sample of the selected potential bioagent particles. The wash assay sample preparation system is operatively connected to the collector and prepares the sample from the air, water, soil, or other substance gathered by the collector. The wash assay sample preparation system includes optically-encoded beads, a number of reagents, a washing buffer, and a detector for detecting any bioagents in the sample.
  • Another embodiment includes a no-wash assay sample preparation system for preparing a sample of the selected potential bioagent particles. The no-wash assay sample preparation system is operatively connected to the collector for preparing the sample from the air, water, soil, or other substance gathered by the collector. The no-wash assay sample preparation system includes optically-encoded beads, a number of reagents, and a detector for detecting any bioagents in the sample.
  • Another embodiment of the present invention provides an apparatus for sampling air and collecting sample particles of a predetermined particle size range from the air for autonomous monitoring air, water, soil, or other substance for bioagents. A low pass section has an opening for gathering said air. A prescreen unit is positioned in the opening that prevents large particles from blocking the opening.
  • The invention is susceptible to modifications and alternative forms. Specific embodiments are shown by way of example. It is to be understood that the invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are incorporated into and constitute a part of the specification, illustrate specific embodiments of the invention and, together with the general description of the invention given above, and the detailed description of the specific embodiments, serve to explain the principles of the invention.
  • FIG. 1 is a block diagram illustrating an embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 2 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 3 is a block diagram illustrating a specific embodiment of the invention designated as an AUTONOMOUS PATHOGEN DETECTION SYSTEM (APDS).
  • FIGS. 4A and 4B are illustrations that show the aerosol collection system.
  • FIGS. 5A and 5B are illustrations that show the cap section limiting the larger particulate size range entering the collector.
  • FIG. 6 is an illustration that shows the virtual impactor section.
  • FIG. 7 shows the multistage, wetted-wall cyclone collector section.
  • FIGS. 8A, 8B, and 8C show details of a specific embodiment of the aerosol collection system.
  • FIG. 9 is an illustration that shows another embodiment of the aerosol collection system.
  • FIG. 10 illustrates a system for sample preparation and detection.
  • FIGS. 11, 12, and 13 illustrate the liquid-array based multiplex immunoassay detection system.
  • FIG. 14 is a block diagram illustrating the multiplex amplification and detection system.
  • FIG. 15 illustrates one specific embodiment of the in-line nucleic acid amplification and detection system.
  • FIG. 16 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 17 is a block diagram illustrating another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention.
  • FIG. 18 illustrates another embodiment of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Referring now to the drawings, to the following detailed description, and to incorporated materials, detailed information about the present invention is provided including the description of specific embodiments. The detailed description and the specific embodiments serve to explain the principles of the invention. The invention is susceptible to modifications and alternative forms. The invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
  • Terrorists sending anthrax-contaminated packages. Militant organizations obtaining potassium cyanide. Religious cult members poisoning local residents to fix an election. Sadly, these scenarios are not the plots of the three latest bestsellers, but rather, very real incidents with a very real danger. By the mid-1990s, the U.S. Congress began to assess the vulnerability of the U.S. civilian population to biological terrorism and found us considerably lacking in our ability to cope with even a small-scale biological event. Initial thinking was that Department of Defense technology could be readily transferred to the civilian arena. However, upon further reflection, it was concluded that although there was overlap between military and civilian defense needs, in the case of a biological threat, there are marked differences: (1) the soldier is trained and equipped with protective gear so he may respond to a threat quickly enough to prevent a lethal dose; (2) military intelligence usually reduces the potential threat to a relatively small number of biological agents; and, (3) military battlefield tactics are designed to minimize the density of soldiers. The civilian population, however, is neither trained nor equipped, is vulnerable to any conceivable pathogen and often gathers in large crowds (special events, sporting venues, etc.) where a small release could potentially infect thousands. In response to these differences, federal agencies, including Department of Energy, have recently begun funding directed research efforts to reduce civilian biological terrorist vulnerabilities.
  • At present there are more than 30 pathogens and toxins on various agency threat lists. Public health personnel rarely see most, of the pathogens so they have difficulty identifying them quickly. In addition, many pathogenic infections aren't immediately symptomatic, with delays as long as several days, limiting options to control the disease and treat the patients. The lack of a practical monitoring network capable of rapidly detecting and identifying multiple pathogens or toxins on current threat lists translates into a major deficiency in the United States ability to counter biological terrorism.
  • Referring now to FIG. 1, an embodiment of an autonomous pathogen detection system constructed in accordance with the present invention is illustrated by a block diagram. The autonomous pathogen detection system is designated generally by the reference numeral 100. The autonomous pathogen detection system 100 provides collection 101, sample preparation 103, and detection 105. The collection 101 includes gathering air, water, soil or other substance to provide an air sample, water sample, soil sample or a sample of other substances.
  • After the collection 101, the sample is transferred as shown by arrow 102 for sample preparation 103. The sample preparation 103 provides an automated sample, an immunoassay sample, and/or a nucleic acid assay sample. In sample preparation 103 the sample may be concentrated, purified, lysed, pulverized or otherwise made to have smaller particulates, mixed, and/or amplified.
  • After sample preparation 103, the sample is transferred as shown by arrow 104 for detection. In one embodiment of the autonomous pathogen detection system 100, the detection is by a multiplex immunoassay detector. In another embodiment of the autonomous pathogen detection system 100, the detection is by a multiplex PCR detector. The detection may also be performed in the same location as the sample preparation, in which case the transfer arrow 104 is not required.
  • The autonomous pathogen detection system 100 provides an apparatus and method for monitoring air, water, soil, or other substance for particles containing bioagents. The autonomous pathogen detection system 100 comprises a collector for gathering the air, water, soil, or other substance being monitored; sample preparation system for preparing a sample from the air, water, soil, or other substance gathered by the collector; and a detector for detecting any bioagents in the sample. In one embodiment the collector is an aerosol collector. In other embodiments the collector gathers water, soil, or other substances. The collector in one embodiment includes separator system for separating the particles of interest from other particles. The particles of interest are of a predetermined size range.
  • In one embodiment the collector is an aerosol collector that collects air and includes a system for separating the air into a bypass air flow that does not contain the particles of a predetermined particle size range and a product air flow that does contain the sample particles of a predetermined particle size range. A wetted-wall cyclone collector receives the product air flow and traps and concentrates the particles of a predetermined particle size range in a liquid.
  • In one embodiment the sample preparation system is automated. In one embodiment the sample preparation system provides an immunoassay sample. In another embodiment the sample preparation system provides a nucleic acid assay sample. In another embodiment the sample preparation system includes concentration of the air, water, soil, or other substance. In another embodiment the sample preparation system includes purification of the air, water, soil, or other substance. In another embodiment the sample preparation system includes lysis of the air, water, soil, or other substance. In another embodiment the sample preparation system includes mixing of the air, water, soil, or other substance. In another embodiment the sample preparation system includes amplification.
  • In one embodiment of the autonomous pathogen detection system 100, the detector is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 100, the detector is a multiplex PCR detector.
  • The primary focus of the autonomous pathogen detection system 100 is the protection of civilians from terrorist attacks; however, the system also has a role in protecting military personnel from biological warfare attacks. The autonomous pathogen detection system 100 also has uses in medical facilities and research and development facilities. The autonomous pathogen detection system 100 has uses in medical monitoring. There are a variety of medical applications where monitoring for biological pathogens would be useful. A good example of this is monitoring in hospitals and clinics for highly infectious agents such as tuberculosis or nosocomial diseases that can threaten the well being of patients and health care professionals. The autonomous pathogen detection system 100 also has uses in environmental monitoring, that is, any application that would benefit from environmental monitoring of biological species. One example is continuous aerosol monitoring of bacterial and other pathogens that could affect the health of livestock (such as the recent hoof and mouth disease outbreak). Another example is continuous aerosol monitoring of viruses that could affect the health of large portions of the population (such as the recent SARS outbreak).
  • Referring now to FIG. 2, another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention is illustrated by a block diagram. This embodiment of the autonomous pathogen detection system is designated generally by the reference numeral 200. The autonomous pathogen detection system 200 provides collection 201, sample preparation 203, detection 205, and confirmation 207. The collection 201 includes gathering air, water, soil or other substance to provide an air sample, water sample, soil sample or a sample of other substances.
  • After the collection 201, the sample is transferred as illustrated by arrow 202 for sample preparation 203. The sample preparation 203 provides an automated sample, an immunoassay sample, and/or a nucleic acid assay sample. In the sample preparation 203 the sample may be concentrated, purified, lysed, pulverized or otherwise made to have smaller particulates, mixed, and/or amplified.
  • After sample preparation 203, the sample is transferred as illustrated by arrow 204 for detection. In one embodiment of the autonomous pathogen detection system 200, the detection is by a multiplex immunoassay detector. In another embodiment of the autonomous pathogen detection system 200, the detection is by a multiplex PCR detector.
  • After sample preparation 203 and detection 205 when a pathogen has been detected, a sample is transferred from sample preparation 203 to the confirmation module 207. This is illustrated by arrow 206 in FIG. 2. In one embodiment, the system for confirmation of a bioagent in the sample is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 200, the system for confirmation of a bioagent in the sample is a multiplex PCR detector. In one embodiment of the autonomous pathogen detection system 200, the system for confirmation of a bioagent in the sample is a real-time PCR detector. The detection may also be performed in the same location as the sample preparation, in which case the transfer arrows 204 and/or 206 are not required.
  • The autonomous pathogen detection system 200 provides an apparatus and method for monitoring air, water, soil, or other substance for particles containing bioagents. The autonomous pathogen detection system 200 comprises a collector for gathering the air, water, soil, or other substance being monitored; sample preparation system for preparing a sample from the air, water, soil, or other substance gathered by the collector; a detector for detecting a bioagents in the sample; and a system for confirmation of a bioagent in the sample. In one embodiment the collector is an aerosol collector. In other embodiments the collector gathers water, soil, or other substances. The collector in one embodiment includes separator system for separating the particles of interest from other particles. The particles of interest are of a predetermined size range.
  • In one embodiment the collector is an aerosol collector that collects air and includes system for separating the air into a bypass air flow that does not contain the particles of a predetermined particle size range and a product air flow that does contain the sample particles of a predetermined particle size range. A wetted-wall cyclone collector receives the product air flow and traps and concentrates the particles of a predetermined particle size range in a liquid.
  • In one embodiment the sample preparation system is automated. In one embodiment the sample preparation system provides an immunoassay sample. In another embodiment the sample preparation system provides a nucleic acid assay sample. In another embodiment the sample preparation system includes concentration of the air, water, soil, or other substance. In another embodiment the sample preparation system includes purification of the air, water, soil, or other substance. In another embodiment the sample preparation system includes lysis of the air, water, soil, or other substance. In another embodiment the sample preparation system includes mixing of the air, water, soil, or other substance. In another embodiment the sample preparation system includes amplification of the sample.
  • In one embodiment of the autonomous pathogen detection system 200, the detector 205 is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 200, the detector 205 is a multiplex PCR detector.
  • In one embodiment of the autonomous pathogen detection system 200, the system 207 for confirmation of a bioagent in the sample is a multiplex immunoassay detector. In one embodiment of the autonomous pathogen detection system 200, the system 207 for confirmation of a bioagent in the sample is a multiplex PCR detector. In one embodiment of the autonomous pathogen detection system 200, the system 207 for confirmation of a bioagent in the sample is a real-time PCR detector.
  • Referring now to FIG. 3 through FIG. 12 a specific embodiment of the invention designated as an AUTONOMOUS PATHOGEN DETECTION SYSTEM (APDS) is shown. The APDS is designated generally by the reference numeral 300. The APDS 300 integrates a flow cytometer and PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins. The APDS 300 is designed for locations where it continuously monitors air samples and automatically reports the presence of specific biological agents. Plague and anthrax are two of the pathogens the APDS 300 identifies, along with a host of others. The APDS 300 includes the potential to measure up to 100 different agents and controls in a single sample.
  • The APDS 300 provides a stand-alone pathogen detection system capable of rapid, continuous, low cost environmental monitoring of multiple airborne biological threat agents. The system 300 provides a “Detect to Protect/Warn” system with a number of key properties. The system 300 is capable of detecting pathogens within a 1-2 hour time window, allowing for enough time to respond to an event. The system 300 is extremely low cost to maintain, since continuous monitoring is essential for many applications. The system 300 has sufficient sensitivity to cover a broad geographical area (limiting the necessary number of sensors) and has sufficient selectivity to virtually eliminate false positives.
  • Multiplexed assays are used to reduce reagent costs, making long term monitoring operations possible. An orthogonal detection section combines antibody-based and nucleic acid-based assays and reduces false positives to a very low level. Antibody assays allow the detector to respond to all types of bioagents, including those without nucleic acids such as protein toxins. Nucleic acid assays allow much more sensitive detection, reducing the number of sensors needed to protect a given area. The fully autonomous aerosol collection and sample preparation capabilities limit maintenance requirements and makes integration into a central security or monitoring network possible.
  • Referring again to FIG. 3, a block diagram illustrates the APDS 300. In operation, an aerosol collector system continuously samples the air and traps particles in a swirling liquid solution. Particles of a given size distribution are selected by varying the flow rate across a virtual impactor unit. The in-line sample preparation system provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performs multiplex detection using a Luminex flow cytometer.
  • In the “detection” sub-system, a collected sample is mixed with optically encoded microbeads. Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead. Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • In the “confirmation” sub-system, PCR amplification and detection of nucleic acids confirms the presence of the bioagent. An archived sample is mixed with the TaqMan real-time PCR reagent, and then introduced by a SIA system into a flow-through polymerase chain reaction (PCR) system. Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the TaqMan probes.
  • In the “Integrated Remote Control and Feedback” sub-system, a central computer uses a simple serial based LabVIEW control system to control all instrument functions. A software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • The APDS 300 is integrated into a self-contained “ATM” style chassis. All fluids and reagents are contained in the instrument. The ADPS 300 includes the following subsystems: Aerosol Collection 301, In-Line Sample Preparation 302, Detection—Liquid-Array Based Multiplex Immunoassay Detection and/or Nucleic Assays Detection 303, Confirmation—In-Line Nucleic Acid Amplification and Detection 304, and Integrated Remote Control and Feedback 305. The subsystem will be described in greater detail.
  • APDS Aerosol Collection—301
  • The first stage of the APADS 300 is “aerosol collection” that provides collection of airborne particles that could contain targeted bioagents. Aerosol release of bioagents is considered one of the possible scenarios of a terrorist organization. One of the methods of rapidly exposing a large population to a biowarfare agent is through use of an aerosol (witness the effect of the recent, relatively small-scale anthrax mailroom releases). The aerosol collection system 301 continuously samples the air and traps particles in a swirling liquid solution. Particles of a given size distribution are selected by varying the flow rate across a virtual impactor unit.
  • The aerosol collection system 301 is a multi-stage aerosol collector that utilizes a low pass aerosol section and a virtual impactor preconcentration that delivers the particles of interest to a wetted wall cyclone collector. The virtual impactor preferentially captures particles 1-10 micrometer (micron) which is the size of particles most likely to be captured in the human lung. In the wetted wall cyclone collector, the particles are collected in a fluid, making downstream processing much easier. The fans and inputs to the obtain high collection rates, up to 3000 liters of air per minute flow through the detection system, allowing many particles to be collected over a short period. The aerosol collection system provides improved sensitivity and reduced collection times. An on-board computer controls air flow rates and the size range of particles collected.
  • As shown by FIGS. 4A and 5A, a very high volume flow of aerosol particles is drawn into an annular slot 401A formed in a cap 402A that is designed to preferentially allow the passage of particles smaller than a pre-set size. The pre-set size can be selected as desired. A very high volume flow of aerosol particles (e.g., up to 3313 Lpm) can be drawn into the annular slot 401A formed in the cap 402A that is designed to preferentially allow the passage of particles smaller than 10 microns. The accepted particles continue on into a dichotomous virtual impaction section 403A that preferentially returns the aerosol particles smaller than 1-micron back into the environment. The remaining particles, (1-10 microns) are known as the product flow. The product flow continues into the next section.
  • As best illustrated by FIG. 5A, a high volume flow of aerosol particles is drawn into the annular slot 401A formed in the cap 402A. The annular slot 401A is designed to limit the upper or larger particulate size range as they enter the collector. To efficiently pass the smaller particulate, the cap 402A is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flow stream (in this case air) will not follow the streamlines exactly due to their inertia. If the curvature of a streamline is sufficiently large and the mass of the particulate is correspondingly high, the particle deviates far enough from the streamline to impact with a surface. The particles are drawn into the annular slot 401A and directed into the transition section 409A.
  • Referring now to FIGS. 4B and 5B, another embodiment of an aerosol collection system is illustrated. This embodiment is designated generally by the reverence numeral 300B. In the embodiment 300B, a very high volume flow of aerosol particles 405B is drawn into an annular slot 401B formed in a cap 402B that is designed to only allow the passage of particles smaller than a pre-set size. The pre-set size can be selected as desired. A very high volume flow of aerosol particles 405B can be drawn into the annular slot 401B formed in the cap 402B that is designed to only allow the passage of particles smaller than 10 microns. A pre-screen 404B prevents large particles from blocking small flow paths such as the flow path 401B. The accepted particles continue on into a dichotomous virtual impaction section 403B that returns all the aerosol particles smaller than 1-micron back into the environment. The remaining particles, (1-10 microns) are known as the product flow. The product flow continues into the next section. (0047) The pre-screen unit 404B in one embodiment is a grill positioned in the opening 401B. The pre-screen unit in another embodiment is a screen positioned in the opening 401B. In another embodiment, the opening 401B in the low pass section is an annular slot and the pre-screen unit 404B is an annular screen positioned in the opening 401B. In another embodiment, the pre-screen 404B is located inside the cap 402B covering the top of the inner cylinder shown as 409B in FIGS. 5A and 5B.
  • As best illustrated by FIG. 5, in the embodiment 300B a high volume flow of aerosol particles 405B is drawn into the annular slot 401B formed in the cap 402B. The annular slot 401B is designed to limit the upper or larger particulate size range as they enter the collector. The embodiment 300B is particularly suited for operating in dirty environments such as subway stations. A prescreen unit 404B is positioned at the entrance to the annular slot 401B to prevent large particles from blocking the small flow paths of the virtual impactor.
  • To efficiently pass the smaller particulate, the cap 402B is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flow stream (in this case air) will not follow the streamlines exactly due to their inertia. If the curvature of a streamline is sufficiently large and the mass of the particulate is correspondingly high, the particle deviates far enough from the streamline to impact with a surface. The particles are drawn through the pre-screen 404B into the annular slot 401B and directed into the transition section 409B. In operation of the embodiment 300B, nightly clean-in-place protocols are implemented to keep the walls of the wetted-wall-cyclone clean using reagents such as dilute bleach and surfactant solutions. Also, the optical bubble counter is cleaned periodically with a pipe-cleaner, catheter, or other such tool.
  • The APDS 300A has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time. The system is entirely self-contained requiring only a 110 V ac power connection. The on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • The APDS 300A is useful for most environmental sampling. It is particularly useful with biological material collection, but can be used for collecting any airborne matter. The APDS 300A can be used to sample air quality in public buildings such as convention centers and sports arenas, for sampling in food processing facilities, sampling animal pens (such as poultry houses), or for use in monitoring orchards or agricultural areas for the presence of pollens or pesticides. Because of its relatively compact size and weight it can be used to sample in confined spaces such as found in aircraft or subway systems.
  • Referring now to FIG. 6, the virtual impactor section 403 is shown in greater detail. In the virtual impactor section 403, the separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle and collection probe. The key is particulate larger than the cut size become concentrated in the minor flow. The concentration factor is the ratio of the total flow to the minor flow. (If the minor flow is 25% of the total flow, then the concentration factor is 4.) The aerosol passes through an acceleration nozzle 601. The acceleration nozzle 601 has a diameter D0. The aerosol is directed toward a collection probe 602. The collection probe has a diameter D1. Between the acceleration nozzle 601 and the collection probe 602, a major portion of the flow 603 is diverted 90° away. The minor or “product” flow 604 continues axially.
  • The flow forms streamlines 605. Small particles with low inertia 606 follow the flow streamlines and are carried away radially with the major flow 603. Large particles with greater inertia 607 deviate from the flowlines but they continue moving axially in their forward path down the collection probe 602 with the minor or “product” flow 604. The separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle D0 and collection probe D1. The key is particulate larger than the cut size become concentrated in the minor flow. The concentration factor is the ratio of the total flow to the minor flow.
  • Referring now to FIG. 7, additional details of the sample collection operation are shown. The particles, (1-10 microns) known as the product flow are directed into a multi-stage, wetted-wall cyclone collection section. In this stage of the sampling system the product particles are trapped and concentrated into a liquid, typically water, in a volume between 2 and 7 cc. An on-board computer monitors and controls the flow of air through the system using built in hot wire anemometers, as well as controlling the liquid level in the cyclone. At a selected time the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the sample via an external liquid sample port.
  • The product flow particles enter a stainless steel funnel section into the input of a multistage, wetted-wall cyclone collector section 700. The system includes a cyclone collector 701, peristaltic pump 707, an air pump 704, a vent 706, wash 705, 8 liter DD-H2O (double deionized water) reservoir 702, and 1 liter bleach reservoir 703. The reservoirs 702 and 703 are provided as external tanks outside of the front panel interface 708. The multistage, wetted-wall cyclone collector section 700 directs the particles of interest to the sample preparation system 302.
  • The on-board computer monitors and controls the flow of air through the system using built in hot wire anemometers that have been mounted in the two exhaust ports of the sampler. The computer and control software also act to control the liquid level in the cyclone, and monitor all status indicators of the sampling system. At a selected time the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the collected liquid sample via an external sample port. The system also has the capability to measure particle sizes in the background environment via a built in particle counter such as particle counter Biotest APC-1000, with four size ranges, and can store and display the results in real-time.
  • The system 300 is entirely self-contained requiring only a 110 vac power connection. The on-board computer has high-speed communications capability allowing networking of multiple sampling systems to be remotely operated. The computer has extra RS-232 or RS-485 serial ports that can be used to control other instrumentation. A keyboard, mouse, printer, displays, and other peripherals can be “plugged” in at the rear of the system, or it can be started “headless” (headless=Without a display, mouse, etc.)
  • Referring now to FIGS. 8A, 8B, and 8C, the APDS Aerosol Collection 301 and APDS In-Line Sample Preparation 302 sub systems are shown in greater detail. The aerosol collection system 301 is designated “High Collection Rate Aerosol Sampling System” (HiCRASS). The HiCRASS comprises: Low Pass “Cap” 402; Transition Section 409; Virtual Impactor 403; Funnel Section 410; Multistage, Wetted-wall Cyclone Collector 700; Bypass Fan 412; and Control Computer 714.
  • The HiCRASS system provides a very high volume flow of aerosol particles (e.g., up to 3313 Lpm) that are drawn into the annular slot 401 formed in the cap 402 that is designed to limit the upper or larger particulate size range as they enter the collector. The annular slot 401 allows the passage of particles smaller than 10 microns. To efficiently pass the smaller particulate, the cap 402 is a “passive” device in that is has no moving parts and uses the fact that particulate with a finite mass and moving in a flowstream (in this case air) will not follow the streamlines exactly due to their inertia. The curvature of the streamline is sufficiently large and the mass of the particulate is correspondingly high that the particle deviates far enough from the streamline to impact with a surface. The accepted particles continue around the corner and onto the dichotomous virtual impaction section 403 that returns substantially all the aerosol particles smaller than 1-micron back into the environment.
  • The virtual impactor 403 works as the aerosol passes through an accelerating nozzle 601 and is directed toward a collection probe 602 where a major portion of the flow 603 is diverted 90° away from it. The flow forms streamlines 605. Small particles with low inertia 606 follow the flow streamlines and are carried away radially with the major flow 603. Large particles with greater inertia 607 deviate from the flowlines but they continue moving axially in their forward path down the collection probe 602 with the minor or “product” flow 604. The separation efficiency is determined by the ratio of the major and minor flows (or Bypass to Product) and the physical dimensions of the nozzle D0 and collection probe D1. Particulate larger than the cut size become concentrated in the minor flow. The concentration factor is the ratio of the total flow to the minor flow. (If the minor flow is 25% of the total flow, then the concentration factor is 4).
  • The remaining particles (1-10 microns) now known as the product 604, flow down a stainless steel funnel section into the input of the multistage, wetted-wall cyclone collector section 700. In this stage of the system 301 the product particles are trapped and concentrated into a liquid, typically water, in a volume between 2 and 7 cc. The wetted-wall cyclone collector section 700 is a system that causes the product flow particles 604 to be collected by a liquid. The wetted-wall cyclone collector section 700 operates by forcing the air stream tangentially into a cylinder causing the air stream to circulate around the inside of the cylinder. Particles in the air stream having sufficient inertia will collide with the interior wall where they are collected by the liquid that circulates along the interior wall.
  • The on-board computer 714 monitors and controls the flow of air through the system using built-in hot wire anemometers, as well as controlling the liquid level in the cyclone 700. At a selected time the computer 714 will stop the flow of air and turn on a built-in peristaltic pump to deliver the sample via an external sample port. The on-board computer 714 monitors and controls the flow of air through the system using built in hot wire anemometers that have been mounted in the two exhaust ports of the sampler. The computer and control software also act to control the liquid level in the cyclone, and monitor all status indicators of the sampling system. At a selected time the computer will stop the flow of air and turn on a built-in peristaltic pump to deliver the collected liquid sample via an external sample port.
  • The system also has the capability to measure particle sizes in the sampling environment via a built in particle counter such as particle counter Biotest APC-1000, with four size ranges, and can store and display the results in real-time. The system is entirely self-contained requiring only a 110 vac power connection. The on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • Referring now to FIG. 9, another embodiment of the collection section of the present invention is illustrated. This collection section system is designated generally by the reference numeral 900. The system 900 samples the air 901 and collects sample particles of a predetermined particle size range from the air. The system 900 is particularly useful with the latest generation of Biological Warfare agent detection systems. An air sampling system is a critical component in integrated biological warfare detection system. The system 900 also has use in medical facilities and research and development facilities.
  • A low pass section 902 has an opening of a preselected size for gathering the air 901 but excluding particles larger than the sample particles. In one embodiment, the opening of a preselected size is an annular slot that only allows the passage of particles smaller than 10 microns. The low pass section 902 produces a total air flow 903 that contains the sample particles of a predetermined particle size range. The low pass section 902 allows a very high volume flow of air to be drawn through the preselected size opening. In one embodiment, the very high volume flow of air is 3313 Lpm or less.
  • An impactor section 904 is connected to the low pass section 902 and receives the total air flow 903. The impactor section 904 separating the total air flow 903 into a bypass air flow 905 that does not contain the sample particles and a product air flow 906 that does contain the sample particles. An accelerating nozzle and a collection probe in the impactor section 904 diverts the bypass air flow 90° from the product air flow thereby separating the bypass air flow and the product air flow. In one embodiment, the bypass air flow and the product air flow separation is determined by the ratio of the bypass air flow and the product air flow. In one embodiment, the bypass air flow and the product air flow separation is determined by the physical dimensions of the accelerating nozzle and the collection probe. In one embodiment, the bypass air flow and the product air flow separation is determined by the ratio of the bypass air flow and the product air flow and the physical dimensions of the accelerating nozzle and the collection probe.
  • A wetted-wall cyclone collector section 907 is connected to the impactor section 904. The wetted-wall cyclone collector section 907 receives the product air flow 906 and traps the sample particles in a liquid. The sample particles of a predetermined particle size range are concentrated in the liquid. In one embodiment, the wetted-wall cyclone collector section 907 traps and concentrates the sample particles into a liquid in a volume between 2 and 7 cc. In one embodiment, the liquid is water.
  • The system 900 is useful for most environmental sampling. It is particularly useful with biological material collection, but can be used for collecting any airborne matter. The system 900 can be used to sample air quality in public buildings such as convention centers and sports arenas, for sampling in food processing facilities, sampling animal pens (such as poultry houses), or for use in monitoring orchards or agricultural areas for the presence of pollens or pesticides. Because of its relatively compact size and weight it can be used to sample in confined spaces such as found in aircraft or subway systems.
  • APDS In-Line Sample Preparation—302
  • As best illustrated in FIG. 3, the in-line sample preparation module 302 moves the sample from the aerosol collection module 301 to appropriate modules within the APDS 300 and provides sample preparation. In one mode, the sample preparation module 302 prepares the sample (mixing, filtering, incubation, etc.) and delivers the sample reaction volume to the liquid-array based multiplex immunoassay detection system 303. In another mode, the sample preparation module 302 prepares the sample (mixing, filtering, incubation, etc.) and delivers the sample reaction volume to the in-line nucleic acid detection system 304.
  • The prior art sample preparation instrumentation uses robotic manipulation of micropipettes coupled to disposable filter wells. Robotics are inherently complex and difficult to scale. The sample preparation module 302 uses Zone fluidics. Zone fluidics is the precisely controlled physical, chemical, and fluid-dynamic manipulation of zones of miscible and immiscible fluids in narrow bore conduits to accomplish sample conditioning and chemical analysis. A zone is a volume region within a flow conduit containing at least one unique characteristic. A unit operation in zone fluidics comprises of a set of fluid handling steps intended to contribute to the transformation of the sample into a detectable species or prepare it for manipulation in subsequent unit operations. Examples of unit operations include sample filtering, dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting. In current analytical practice many of these steps are handled manually or in isolated pieces of equipment. Integration is scant at best, and there is a high degree of analyst involvement. In zone fluidics, sample and reagent zones are subjected to these unit operations in a sequential manner being transported from one unit operation to the next under fluidic control.
  • Samples in zone fluidics are not limited to liquids. Rather, gases, and suspensions containing solids or cells are also included. Where solid samples are used, particles are limited to a size that ensures no blockages. In most cases, reagents are prepared and then coupled to the zone fluidics manifold. The metering capability of the pump and mixing unit operations allow for reagents and standards to be prepared in situ. Reagents can therefore be presented to the zone fluidics manifold in an appropriately designed cartridge as ready-made, reagent concentrates, lyophilized, or crystalline form. Standards can be plumbed to the multi-position valve as discrete reservoirs providing the required range of concentrations. As for reagents though, standards can also be prepared in situ or diluted to cover a larger dynamic range.
  • The sample preparation module 302 uses a powerful, highly flexible technique called sequential injection analysis (SIA). Automation is achieved through the manipulation of small solution zones under conditions of controlled dispersion in narrow bore tubing. Zone fluidics makes use of a multi-position selection valve and a high precision, bi-directional pump to construct a stack of well-defined sample and reagent zones in a holding coil of narrow bore tubing. By appropriate manipulation of this zone stack, a wide range of sample handling unit operations can be accommodated. The pump is used to move the sample from one device to the next achieving the required sample manipulation in the process. Once a detectable species has been formed, the zone stack is transported to the immunoassay detector 303 and to the nucleic acid detector 304.
  • Various embodiments of system for sample preparation and detection have been described in connection with FIGS. 10-13. Applicants will now describe additional embodiments of the immunoassay system of the present invention. These embodiments of the immunoassay system can use either “wash assay” system or “no-wash assay” system. The “wash assay” system and the “no-wash assay” system use optically-encoded beads. The beads are kept in a small (˜15 mL) stirred tank. Bead loss from agglomeration is reduced by using dispersing agents such as ethanol in the bead slurry. This reduces reagent cost.
  • The wash assay system embodiment uses a number of reagents in addition to the liquid sample. The reagents include detector antibody, and fluorescent reporter (streptavidin-phycoerythrin). In the wash assay system, a bed of beads is deposited on a filter then exposed to the sample, washing buffer, detector antibody, washing buffer, fluorescent reporter, washing buffer, and then the beads are released to the detector. For the wash assay system, the bead filter performance in releasing beads is improved by implementing frequent clean-in-place protocols using reagents such as bleach for cleaning and morpholine propane sulfonic acid (MOPS) citrate buffer for reconditioning the filter. This extends the time between servicing the instrument and thus reduces operating cost.
  • In the no-wash assay embodiment, the reagents are sequentially mixed but the embodiment does not include the filter or the wash steps. It has been shown that the wash assays are more sensitive and selective, providing better signal-to-noise ratios in response to bioagents.
  • Referring now to FIG. 14, another embodiment of a system constructed in accordance with the present invention is illustrated. The system is designated generally by the reference numeral 1400. The system 1400 comprises the following: Sample Collection 1401, Sample Preparation 1402, Multiplex Amplification PCR 1403, and Multiplex, Liquid Array Based Detection of PCR Amplicons 1404.
  • The first stage of the system 1400 is “sample collection 1401” that provides collection of particles that could contain targeted bioagents. The sample collection 1401 gathers air, water, soil, or other substance being monitored. The sample collection 1401 separates selected potential bioagent particles from the air, water, soil, or other substance.
  • The “sample preparation 1402” moves the sample from the sample collection to appropriate modules within the system 1400 and provides sample preparation. In one mode, the sample preparation 1402 prepares the sample (Lysis, Concentration, Purification, Mixing, etc.) and delivers the sample to “Multiplex Amplification PCR 1403.” One mode provides “Multiplex, Liquid Array Based Detection of PCR Amplicons 1404.” An example of a flow cytometric detection method for DNA samples is shown in U.S. patent application 2002/0155482 by Shanavaz Nasarabadi, Richard G. Langlois, and Kodumudi Venkateswaran published Oct. 24, 2002. The disclosure of U.S. patent application 2002/0155482 is incorporated herein by reference.
  • Referring now to FIG. 15, one specific embodiment of the in-line nucleic acid amplification and detection system 1500 is illustrated. The system 1500 is capable of performing, singly or in combination, nucleic acid amplification, and nucleic acid detection functions. The nucleic acid assay system 1500 includes a number of components including system for injecting/aspirating a sample, 1501, system for adding PCR reagent 1502, system for mixing sample and reagent 1503, system for transport to PCR reactor 1504, system for performing PCR amplification 1505, system for transport of amplified sample from PCR reactor 1506, system for detection of PCR amplicons 1507, and system for decontamination and conditioning of all exposed conduits 1508.
  • The system 1501 for injecting and or aspirating a sample provides injection and/or aspiration of the sample. In one embodiment the injecting/aspirating system 1501 consists of a zone fluidics system. In another embodiment the injecting/aspirating system 1501 consists of an FIA system. The system 1501 for injecting and or aspirating a sample can be, for example, a injecting/aspirating device available under the trademark milliGAT™ pump, Global FIA, Inc., Fox Island, Wash.
  • The system 1502 for adding PCR reagent to the sample is operatively connected to the system 1501 for injecting and or aspirating a sample. The system 1502 for adding PCR reagent to the sample can be, for example, a unit for adding PCR reagent to the sample such as an injection or multi position selection valve, available from VICI, Houston, Tex.
  • The system 1503 for mixing the sample and the reagent is operatively connected to the system 1502 for adding PCR reagent to the sample. The mixing system 1503 mixes the sample with a PCR reagent. In one embodiment the PCR reagent includes primers. In another embodiment the PCR reagent includes oligos. The system 1503 for mixing the sample and the reagent can be, for example, a super serpentine reactor, available from Global FIA, Inc., Fox Island, Wash.
  • The system 1504 for transporting the sample and the reagent to a PCR reactor is operatively connected to the system 1503 for mixing the sample and the reagent. The system 1504 for transporting the sample and the reagent to a PCR reactor consists of a fluidics system. The system 1504 for transporting the sample and the reagent to a PCR reactor can be, for example, FEP tubing available from Cole-Parmer, Vernon Hills, Ill.
  • The system 1505 for performing PCR amplification is operatively connected to the system 1504 for transporting the sample and the reagent to a PCR reactor. This results in an amplified sample. In one embodiment the PCR amplification system 1505 includes an embedded thermocouple calibration conduit. PCR amplification devices are described in publications such as U.S. Pat. No. 5,589,136 for silicon-based sleeve devices for chemical reactions, assigned to the Regents of the University of California, inventors: M. Allen Northrup, Raymond P. Mariella, Jr., Anthony V. Carrano, and Joseph W. Balch, patented Dec. 31, 1996 and many are commercially available such as ABI PRISM® 7700 Sequence Detection System by Applied Biosystems; iCycler iQ Real-Time PCR Detection System by Bio-Rad; and Smart Cycler® System by Cepheid.
  • The system 1506 for transporting the amplified sample from the PCR reactor is operatively connected to the system 1205 for performing PCR amplification. The system 1506 for transporting the amplified sample from the PCR reactor can be, for example, FEP tubing available from Cole-Parmer, Vernon Hills, Ill.
  • The system 1507 for detection of PCR amplicons is operatively connected to the system 1506 for transporting the amplified sample from the PCR reactor. The system 1507 for detection of PCR amplicons can be, for example, a detection system described in publications and products produced by Cepheid and Baltimore-based Environmental Technologies Group, Inc. (ETG), a part of London-based Smiths Aerospace.
  • Conduits are included within the system 1501 for injecting and or aspirating a sample, system 1502 for adding PCR reagent to the sample, system 1503 for mixing the sample and the reagent, system 1504 for transporting the sample and the reagent to a PCR reactor, system 1505 for performing PCR amplification, system 1506 for transporting the amplified sample from the PCR reactor, and system 1507 for detection of PCR amplicons. A system 1508 for decontamination and conditioning the conduits is directly connected to the system 1507 for detection of PCR amplicons. The system 1508 for decontamination and conditioning the conduits is operatively connected to the system 1501 for injecting and or aspirating a sample, system 1502 for adding PCR reagent to the sample, system 1503 for mixing the sample and the reagent, system 1504 for transporting the sample and the reagent to a PCR reactor, system 1505 for performing PCR amplification, system 1506 for transporting the amplified sample from the PCR reactor, and system 1507 for detection of PCR amplicons. The decontamination and conditioning of all exposed conduits can be, for example, be performed by using a decontaminant, such as bleach, which is pumped through the exposed conduits and then washed from the system with a suitable wash solution.
  • Referring now to FIG. 16, a block diagram illustrates another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention. This embodiment of an autonomous pathogen detection system is designated generally by the reference numeral 1600. The autonomous pathogen detection system 1600 provides water sample collection 1601, sample preparation 1602, and detection 1603 and 1604.
  • In operation, a water sample collection unit 1601 continuously samples a water source. Water sampling systems are known in the art. For example, a water sampling system is shown in U.S. Pat. No. 6,306,350 issued Oct. 23, 2001 titled “Water Sampling Method and Apparatus With Analyte Integration.” The disclosure of U.S. Pat. No. 6,306,350 is incorporated herein by reference.
  • The in-line sample preparation unit 1602 concentrates the sample in a swirling buffer solution. Particles of a given size distribution are selected by varying the flow rate across a separator unit. The in-line sample preparation system 1602 provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performing multiplex detection using a Luminex flow cytometer.
  • In the “detection” sub-system 1603, a collected sample is mixed with optically encoded microbeads. Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead. Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • In the “confirmation” sub-system 1604, PCR (nucleic acid) amplification and detection confirms the presence of the bioagent. An archived sample is mixed with the Taqman reagent, and then introduced by a SIA system into a flow through polymerase chain reaction (PCR) system. Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the Taqman probes. In the “Integrated Remote Control and Feedback” sub-system 1605, a central computer uses a simple serial based LabVIEW control system to control all instrument functions. A software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • The first stage of the system 1600 is “water sample collection 1601” that provides collection of particles from a source of water that could contain bioagents. The water sample collection system 1601 and in-line sample preparation 1602 provide preconcentration and delivery of the particles of interest to a wetted wall cyclone collector. The separator system captures particles of interest.
  • In the wetted wall cyclone collector, the particles are collected in a fluid, making downstream processing much easier. An on board computer controls water flow rates and the size range of particles collected. A particle counter provides real-time feedback on the size and quantity of particles collected.
  • Particles are drawn into the system that is designed to only allow the collection of particles of a pre-set size. The pre-set size can be selected as desired. The system is designed to only collect particles that are desired. The accepted particles continue on into a separator section that returns all the particles that are not of the desired size back into the environment. The remaining particles are known as the product flow. The product flow continues into the detection sections.
  • The system 1600 has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time. The system is entirely self-contained requiring only a power connection. The on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated.
  • The 1600 is useful for many application of water sampling. The system 1600 can be used to sample water quality in public buildings, for sampling in food processing facilities, for use in monitoring agricultural areas for the presence of pollens or pesticides and other water sampling uses.
  • Referring now to FIG. 17, a block diagram illustrates another embodiment of an autonomous pathogen detection system constructed in accordance with the present invention. This embodiment of an autonomous pathogen detection system is designated generally by the reference numeral 1700. The autonomous pathogen detection system 1700 provides soil sample collection 1701, sample preparation 1702, and detection 1703 and 1704.
  • In operation, a soil sample collection unit 1701 continuously samples a soil source. Soil sampling systems are known in the art. For example, a soil sampling system is shown in U.S. Pat. No. 6,363,803 titled “Vehicle Mounted Soil Sampler,” invented by Elmer Hubers, patented Apr. 2, 2002. The disclosure of U.S. Pat. No. 6,363,803 is incorporated herein by reference.
  • The in-line sample preparation unit 1702 concentrates the sample in a swirling buffer solution. Particles of a given size distribution are selected by varying the flow rate across a separator unit. The in-line sample preparation system 1702 provides all sample preparation steps (i.e., mix, wash, incubation, etc.), and performing multiplex detection using a Luminex flow cytometer.
  • In the “detection” sub-system 1703, a collected sample is mixed with optically encoded microbeads. Each color of microbead contains a capture assay that is specific for a given bioagent. Fluorescent labels are added to identify the presence of each agent on the bound bead. Each optically encoded and fluorescently labeled microbead is individually read in a flow cytometer, and fluorescent intensities are then correlated with bioagent concentrations.
  • In the “confirmation” sub-system 1704, PCR (nucleic acid) amplification and detection confirms the presence of the bioagent. An archived sample is mixed with the TaqMan reagent, and then introduced by a SIA system into a flow through polymerase chain reaction (PCR) system. Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the TaqMan probes. In the “Integrated Remote Control and Feedback” sub-system 1705, a central computer uses a simple serial based LabVIEW control system to control all instrument functions. A software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • The first stage of the system 1700 is “soil sample collection 1701” that provides collection of particles from a source of soil that could contain bioagents. The soil sample collection system 1701 and in-line sample preparation 1702 provide preconcentration and delivery of the particles of interest to a wetted wall cyclone collector. The separator system captures particles of interest.
  • In the wetted wall cyclone collector, the particles are collected in a fluid, making downstream processing much easier. An on board computer controls soil flow rates and the size range of particles collected. A particle counter provides real-time feedback on the size and quantity of particles collected.
  • Particles are drawn into the system that is designed to only allow the collection of particles of a pre-set size. The pre-set size can be selected as desired. The system is designed to only collect particles that are desired. The accepted particles continue on into a separator section that returns all the particles that are not of the desired size back into the environment. The remaining particles are known as the product flow. The product flow continues into the detection sections.
  • The system 1700 has the capability to measure particle sizes in the sampling environment via a built in particle counter with four size ranges, and can store and display the results in real-time. The system is entirely self-contained requiring only a power connection. The on-board computer has high-speed communications capability allowing networks of these sampling systems to be remotely operated. The 1700 is useful for many application of soil sampling. The system 1700 can be used to sample soil quality in monitoring agricultural areas for the presence of pollens or pesticides and other soil sampling uses.
  • Referring now to FIG. 18, another embodiment of a system for sample preparation and detection is illustrated. The system is generally designated by the reference numeral 1800. The system 1800 is capable of performing, singly or in combination, liquid-array based multiplex immunoassay detection and/or in-line nucleic acid amplification and detection. In operation of the system 1800, the aerosol collector system 1801 samples the air, particles of a given size distribution are trapped in a liquid, and a sample of interest is prepared. The next step is detection of any pathogens in the sample particles. This is accomplished by a liquid-array based multiplex immunoassay detection system 1802 and an in-line nucleic acid amplification and detection system 1803.
  • The liquid-array based immunoassay detection system 1802 measures multiple pathogen targets in the sample. The immunoassay system 1802 can use either “wash assay” system or “no-wash assay” system. The “wash assay” system and the “no-wash assay” system use optically-encoded beads. The beads are kept in a small (˜15 mL) stirred tank. Bead loss from agglomeration is reduced by using dispersing agents such as ethanol in the bead slurry. This reduces reagent cost.
  • The wash assay system embodiment uses a number of reagents in addition to the liquid sample. The reagents include detector antibody, and fluorescent reporter (streptavidin-phycoerythrin). In the wash assay system, a bed of beads is deposited on a filter then exposed to the sample, washing buffer, detector antibody, washing buffer, fluorescent reporter, washing buffer, and then the beads are released to the detector. For the wash assay system, the bead filter performance in releasing beads is improved by implementing frequent clean-in-place protocols using reagents such as bleach for cleaning and morpholine propane sulfonic acid (MOPS) citrate buffer for reconditioning the filter. This extends the time between servicing the instrument and thus reduces operating cost.
  • In the no-wash assay embodiment, the reagents are sequentially mixed but the embodiment does not include the filter or the wash steps. It has been shown that the wash assays are more sensitive and selective, providing better signal-to-noise ratios in response to bioagents.
  • The PCR (nucleic acid) amplification and detection system 1803 confirms the presence of any bioagent. An archived sample is mixed with the TaqMan reagent, and then introduced by a system into a flow through polymerase chain reaction (PCR) system. Specific nucleic acid signatures associated with the targeted bioagent are amplified and detected using fluorescence generated from nucleic acid replication from the TaqMan probes.
  • The PCR assays for confirming immunoassay positives are implemented using real-time PCR and the TaqMan process. Both FAM and TAMRA dyes are used as TaqMan reporters and TAMRA and BHQ (Black Hole Quencher) dyes are used as TaqMan quenchers. In one embodiment the FAM-BHQ is used for the bioagent probe and TAMRA-BHQ for an internal control probe. This allows an internal control to be used on a two-color detector. Internal controls are critical in PCR due to the delicacy of the reaction; otherwise, negative results are not definitive. In one embodiment, two color excitation is used to give strong signals for duplexed TaqMan PCR (agent plus internal control).
  • In some embodiments, the PCR reagents for TaqMan PCR are stored on the system together as MasterMix (enzyme, buffer, dNTPs) mixed with primers and probes. In another embodiment it was found that storing the MasterMix in one reservoir and primers plus probes in another reservoir made the reagents more stable, potentially eliminating the need for cooling in the instrument. In one embodiment, extraction of DNA onto microfabricated silica pillars is used as a means of purifying DNA from PCR inhibitors.
  • Sample preparation moves the sample from the sample collection 1801 to appropriate modules within the system. The nucleic acid assay system 1803 includes a number of components including system for injecting/aspirating a sample, system for adding PCR reagent, system for mixing sample and reagent, system for transport to PCR reactor, system for performing PCR amplification, system for transport of amplified sample from PCR reactor for detection of PCR amplicons. A central computer 1805 uses a simple serial based LabVIEW control system to control all instrument functions. A software system provides data acquisition, real-time data analysis, and result reporting via a graphical user interface.
  • In operation of the pathogen detection system, the in-line nucleic acid amplification and detection system provides nucleic acid assay methods. The methods include a number of steps. One step consists of automatically injecting and or aspirating a sample. Another step consists of automatically adding PCR reagent to the sample. Another step consists of automatically mixing the sample and the reagent. Another step consists of automatically transporting the sample and the reagent to a PCR reactor. The PCR reactor consists of a fluidics system. Another step consists of automatically performing PCR amplification resulting in an amplified sample. Another step consists of automatically transporting the amplified sample from the PCR reactor. Another step consists of automatically detecting PCR amplicons. The method is performed in a nucleic acid assay system and the nucleic acid assay system is decontaminated and conditioned before a new sample is analyzed.
  • The system includes both real-time and post-PCR detection. The system is ideal for monitoring type systems, such as those currently being developed to detect terrorist releases of aerosolized bioagents. On-site detection systems for infectious diseases under development will need to incorporate sample preparation and analysis functions. The system allows relatively unskilled personnel, such as early responders, to perform real-time field or point-of-care nucleic acid assays. In various other embodiments of the autonomous pathogen detection system, the confirmation of bioagent(s) in the sample is provided by a multiplex immunoassay detector, a multiplex PCR detector, and a real-time PCR detector.
  • The present invention provides an Autonomous Pathogen Detection System (APDS) for monitoring the environment to protect the public from the release of hazardous biological agents. The Autonomous Pathogen Detection System is a countermeasure to bioterrorism, one of the most serious threats to the safety of United States citizens, citizens of other countries, and the military.
  • The APDS program was initiated to fill the requirement of a distributed environmental monitoring system for civilian applications. Multiplexed assays are used to reduce reagent costs, making long term monitoring operations possible (e.g., U.S. Postal Service mail screening). A unique, orthogonal detection approach that combines antibody-based and nucleic acid-based assays reduces false positives to a very low level. Antibody assays allow the detector to respond to all types of bioagents, including those without nucleic acids such as protein toxins. Nucleic acid assays allow much more sensitive detection, reducing the number of sensors needed to protect a given area. The fully autonomous aerosol collection and sample preparation capabilities limit maintenance requirements and makes integration into a central security or monitoring network possible.
  • There are other environmental or clinical pathogen detection system needs. Mobile units could be transported to suspected “sick buildings” to test for mold or fungal spores that might be causing tenant illnesses. Units with reagents for animal diseases could be placed in livestock transport centers or feedlots to rapidly detect airborne pathogens and protect against disease outbreaks. Monitors in hospitals could be used to test for airborne spread of contagious materials among patients. The system could be used at high profile events such as the Olympics for short-term, intensive monitoring or more permanent installation in major public buildings or transportation nodes. All of the individual units can be networked to a single command center so that a small group of technical experts can maintain and respond to alarms at any of the units. The system is capable of meeting all of these needs.
  • The primary needs describe above are directed to protection of civilians from terrorist attacks. The system also has uses in protecting military personnel from biological warfare attacks. The military continues to evaluate options to their current biowarfare detection systems and the system meets many of the needs of the military.
  • While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims (22)

1. An autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents that could be in potential bioagent particles, comprising:
collector means for gathering said air, water, soil, or other substance being monitored, said collector separating the potential bioagent particles from said air, water, soil, or other substance;
sample preparation means for preparing a sample of the potential bioagent particles, said sample preparation means operatively connected to said collector means for preparing said sample from said air, water, soil, or other substance gathered by said collector;
detector means for detecting said bioagents in said sample, said detector means comprising a liquid-array based multiplex immunoassay detector and a multiplex PCR detector.
2. The apparatus of claim 1 wherein said sample preparation means is a means for providing an immunoassay sample.
3. The apparatus of claim 2 wherein said means for providing an immunoassay sample is a multiplex immunoassay detector that utilizes optically encoded microbeads.
4. The apparatus of claim 1 wherein said sample preparation means is a means for providing a nucleic acid assay sample.
5. The apparatus of claim 1 wherein said multiplex PCR detector is a real time PCR detector.
6. The apparatus of claim 1 wherein said multiplex PCR detector includes means for performing PCR amplification.
7. An autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents, the bioagents potentially being in potential bioagent particles within the air, water, soil, or other substance, comprising:
a collector for gathering said air, water, soil, or other substance being monitored, said collector separating selected potential bioagent particles from said air, water, soil, or other substance;
a wash assay sample preparation system for preparing a sample of said selected potential bioagent particles, said wash assay sample preparation system operatively connected to said collector for preparing said sample from said air, water, soil, or other substance gathered by said collector; said wash assay sample preparation system including optically-encoded beads, a number of reagents, and a washing buffer; and
a detector for detecting the bioagents in said sample, said detector operatively connected to said sample preparation system.
8. The apparatus of claim 7 wherein said reagents include detector antibodies.
9. The apparatus of claim 7 wherein said reagents include fluorescent reporters.
10. The apparatus of claim 7 wherein said wash assay sample preparation system includes a filter.
11. The apparatus of claim 7 wherein said wash assay sample preparation system includes a filter and optically-encoded beads.
12. An autonomous monitoring apparatus for monitoring air, water, soil, or other substance for bioagents, the bioagents potentially being in potential bioagent particles within the air, water, soil, or other substance, comprising:
a collector for gathering said air, water, soil, or other substance being monitored, said collector separating selected potential bioagent particles from said air, water, soil, or other substance;
a no-wash assay sample preparation system for preparing a sample of said selected potential bioagent particles, said no-wash assay sample preparation system operatively connected to said collector for preparing said sample from said air, water, soil, or other substance gathered by said collector; said no-wash assay sample preparation system including optically-encoded beads and a number of reagents; and
a detector for detecting the bioagents in said sample, said detector operatively connected to said sample preparation system.
13. An apparatus for sampling air and collecting sample particles of a predetermined particle size range from said air for monitoring air, water, soil, or other substance for bioagents, the bioagents potentially being in potential bioagent particles within the air, water, soil, or other substance, comprising:
a low pass section having an opening for gathering said air,
a pre-screen unit positioned in said opening that prevents large particles from blocking said opening,
an impactor section operatively connected to said low pass section, said impactor section receiving said air and separating said air into a bypass air flow that does not contain said sample particles and a product air flow that contains said sample particles, and
a sample preparation system for preparing a sample of the potential bioagent particles, said sample preparation system operatively connected to said impactor section for preparing said sample; and
a detector for detecting the bioagents in said sample, said detector operatively connected to said sample preparation system.
14. The apparatus of claim 13 wherein said opening in said low pass section size is a slot and said pre-screen unit is a grill positioned in said opening.
15. The apparatus of claim 1 wherein said opening in said low pass section size is a slot and said pre-screen unit is a screen positioned in said opening.
16. The apparatus of claim 13 wherein said opening in said low pass section size is an annular slot and said pre-screen unit is an annular screen positioned in said opening.
17. A method of monitoring air, water, soil, or other substance for bioagents, said air, water, soil, or other substance containing potential bioagent particles of various sizes, comprising the steps of:
gathering said air, water, soil, or other substance containing potential bioagent particles of various sizes;
separating said potential bioagent particles by size and collecting said potential bioagent particles of a size range that are likely to contain said bioagents; and
detecting said bioagents in said potential bioagent particles of a size range that are likely to contain said bioagents, said step of detecting said bioagents comprising mixing optically encoded microbeads with said potential bioagent particles and detecting said bioagents with said optically encoded microbeads.
18. The method of monitoring air, water, soil, or other substance for bioagents of claim 17 wherein said step of detecting said bioagents comprises exposing said microbeads to said air, water, soil, or other substance; depositing said microbeads on a filter; exposing said microbeads to a washing buffer, and releasing said microbeads to a detector.
19. The method of monitoring air, water, soil, or other substance for bioagents of claim 17 wherein said washing buffer comprises buffer solutions.
20. The method of monitoring air, water, soil, or other substance for bioagents of claim 18 wherein steps following releasing said microbeads to a detector includes using cleaning reagents for reconditioning said filter.
21. The method of monitoring air, water, soil, or other substance for bioagents of claim 20 wherein said cleaning reagents include bleach.
22. The method of monitoring air, water, soil, or other substance for bioagents of claim 20 wherein said cleaning reagents include morpholine propane sulfonic acid (MOPS) citrate buffer.
US11/000,491 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents Abandoned US20060057599A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/000,491 US20060057599A1 (en) 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40615902P 2002-08-26 2002-08-26
US10/643,797 US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents
US11/000,491 US20060057599A1 (en) 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/643,797 Continuation-In-Part US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents

Publications (1)

Publication Number Publication Date
US20060057599A1 true US20060057599A1 (en) 2006-03-16

Family

ID=31891539

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/643,797 Abandoned US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents
US11/000,491 Abandoned US20060057599A1 (en) 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents
US11/159,008 Abandoned US20050239192A1 (en) 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays
US12/786,248 Expired - Fee Related US9052255B2 (en) 2002-08-26 2010-05-24 System for autonomous monitoring of bioagents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/643,797 Abandoned US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/159,008 Abandoned US20050239192A1 (en) 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays
US12/786,248 Expired - Fee Related US9052255B2 (en) 2002-08-26 2010-05-24 System for autonomous monitoring of bioagents

Country Status (6)

Country Link
US (4) US20040038385A1 (en)
EP (1) EP1576353A2 (en)
JP (1) JP2006508371A (en)
AU (1) AU2003304254B2 (en)
CA (1) CA2496128A1 (en)
WO (1) WO2005001435A2 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US20070053188A1 (en) * 2005-09-06 2007-03-08 Luminator Holding, L.P. LED ultraviolet air sanitizer light fixture
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection
US20080048874A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20080166793A1 (en) * 2007-01-04 2008-07-10 The Regents Of The University Of California Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US20080168752A1 (en) * 2006-12-22 2008-07-17 Perma Pure, Llc Separating particulate-containing gas flow into particulate and non-particulate flow portions
US20080183433A1 (en) * 2007-01-30 2008-07-31 The Regents Of The University Of California Detection and quantification system for monitoring instruments
WO2008108792A2 (en) * 2006-08-24 2008-09-12 Microfluidic Systems, Inc. An integrated airborne substance collection and detection system
US20080254467A1 (en) * 2007-03-02 2008-10-16 John Frederick Regan Automated High-Throughput Flow-Through Real-Time Diagnostic System
WO2008097250A3 (en) * 2006-08-24 2008-10-16 Microfluidic Systems Inc An integrated airborne substance collection and detection system
US20090263794A1 (en) * 2008-04-21 2009-10-22 Shanavaz Nasarabadi High Throughput Flow Through Sample Preparation Using Magnetic Beads
US20100015601A1 (en) * 2004-11-24 2010-01-21 Invitrogen Corporation Biological confirmation and detection system
US20100050749A1 (en) * 2008-08-28 2010-03-04 MicroFluidic Systems, Ltd. Sample preparation apparatus
USRE41780E1 (en) 2003-03-14 2010-09-28 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning in an immiscible liquid
US20110053798A1 (en) * 2009-09-02 2011-03-03 Quantalife, Inc. System for mixing fluids by coalescence of multiple emulsions
US20110086780A1 (en) * 2008-09-23 2011-04-14 Quantalife, Inc. System for forming an array of emulsions
US20110212516A1 (en) * 2008-09-23 2011-09-01 Ness Kevin D Flow-based thermocycling system with thermoelectric cooler
US20130079236A1 (en) * 2011-09-25 2013-03-28 Theranos, Inc., a Delaware Corporation Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US8663920B2 (en) 2011-07-29 2014-03-04 Bio-Rad Laboratories, Inc. Library characterization by digital assay
US8697377B2 (en) 2007-10-02 2014-04-15 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US8730479B2 (en) 2010-03-25 2014-05-20 Bio-Rad Laboratories, Inc. Detection system for droplet-based assays
WO2014127379A1 (en) * 2013-02-18 2014-08-21 Theranos, Inc. Systems and methods for multi-analysis
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US8994556B2 (en) 2012-05-24 2015-03-31 Douglas H. Lundy Threat detection system and method
US9089844B2 (en) 2010-11-01 2015-07-28 Bio-Rad Laboratories, Inc. System for forming emulsions
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9222128B2 (en) 2011-03-18 2015-12-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9347059B2 (en) 2011-04-25 2016-05-24 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9393560B2 (en) 2010-03-25 2016-07-19 Bio-Rad Laboratories, Inc. Droplet transport system for detection
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9464981B2 (en) 2011-01-21 2016-10-11 Theranos, Inc. Systems and methods for sample use maximization
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9500664B2 (en) 2010-03-25 2016-11-22 Bio-Rad Laboratories, Inc. Droplet generation for droplet-based assays
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9645143B2 (en) 2011-09-25 2017-05-09 Theranos, Inc. Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20170191993A1 (en) * 2014-05-28 2017-07-06 Tokyo Electron Limited Measurement Device and Measurement Method
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US11162936B2 (en) 2011-09-13 2021-11-02 Labrador Diagnostics Llc Systems and methods for multi-analysis
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120183A2 (en) * 2007-12-20 2009-10-01 Biotrove, Inc. System for the detection of a biological pathogen and use thereof
CA2290731A1 (en) * 1999-11-26 2001-05-26 D. Jed Harrison Apparatus and method for trapping bead based reagents within microfluidic analysis system
US6432290B1 (en) 1999-11-26 2002-08-13 The Governors Of The University Of Alberta Apparatus and method for trapping bead based reagents within microfluidic analysis systems
US20030027135A1 (en) * 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20040121313A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in organs for transplantation
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7424013B1 (en) 2001-12-20 2008-09-09 Applied Micro Circuits Corporation System and method for granting arbitrated bids in the switching of information
US8418129B1 (en) 2001-12-14 2013-04-09 Qualcomm Incorporated Method for automatically generating code to define a system of hardware elements
US7352694B1 (en) * 2001-12-14 2008-04-01 Applied Micro Circuits Corporation System and method for tolerating data link faults in a packet communications switch fabric
EP1578399A4 (en) 2002-12-06 2007-11-28 Isis Pharmaceuticals Inc Methods for rapid identification of pathogens in humans and animals
AU2003303594A1 (en) * 2002-12-30 2004-07-29 The Regents Of The University Of California Methods and apparatus for pathogen detection and analysis
WO2004083806A2 (en) * 2003-01-22 2004-09-30 University Of South Florida Autonomous genosensor apparatus and methods for use
US8046171B2 (en) * 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) * 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) * 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US20080138808A1 (en) * 2003-09-11 2008-06-12 Hall Thomas A Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20100035239A1 (en) * 2003-09-11 2010-02-11 Isis Pharmaceuticals, Inc. Compositions for use in identification of bacteria
US20120122103A1 (en) * 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US20060240412A1 (en) * 2003-09-11 2006-10-26 Hall Thomas A Compositions for use in identification of adenoviruses
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
WO2005078674A2 (en) * 2003-12-10 2005-08-25 Smiths Detection Inc. Autonomous surveillance system
WO2005079340A2 (en) * 2004-02-13 2005-09-01 Lacasse Photoplastics, Inc. Intelligent directional fire alarm system
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) * 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
ES2641832T3 (en) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by setting digital thresholds
US20050266411A1 (en) * 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7799553B2 (en) 2004-06-01 2010-09-21 The Regents Of The University Of California Microfabricated integrated DNA analysis system
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
CN101073002B (en) 2004-09-15 2012-08-08 英特基因有限公司 Microfluidic devices
JP4765059B2 (en) * 2005-02-10 2011-09-07 国立大学法人北海道大学 Cognitive task response measurement system and cognitive task response measurement method
US20060281101A1 (en) * 2005-02-17 2006-12-14 The Regents Of The University Of California Biobriefcase
US8084207B2 (en) * 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
WO2006094238A2 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US20070026426A1 (en) 2005-04-26 2007-02-01 Applera Corporation System for genetic surveillance and analysis
AU2006272776B2 (en) * 2005-07-21 2012-01-19 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US7503230B2 (en) * 2005-11-08 2009-03-17 Lawrence Livermore National Security, Llc Biobriefcase aerosol collector heater
WO2008030631A2 (en) * 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Microfluidic devices
US7766033B2 (en) 2006-03-22 2010-08-03 The Regents Of The University Of California Multiplexed latching valves for microfluidic devices and processors
WO2008054480A2 (en) * 2006-03-22 2008-05-08 Northrop Grumman Corporation Enhanced biohazard detection system
DE102006025200A1 (en) * 2006-05-29 2007-12-06 Francotyp-Postalia Gmbh Closing fluid for security closures
US9383322B2 (en) 2006-05-29 2016-07-05 Fracotyp-Postalia GmbH Kit containing sealing liquid for safety closures
US20070292889A1 (en) * 2006-06-16 2007-12-20 The Regents Of The University Of California Immunoassay magnetic trapping device
EP2064332B1 (en) * 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8841116B2 (en) 2006-10-25 2014-09-23 The Regents Of The University Of California Inline-injection microdevice and microfabricated integrated DNA analysis system using same
EP2109666A4 (en) 2007-02-05 2011-09-14 Integenx Inc Microfluidic and nanofluidic devices, systems, and applications
WO2008104002A2 (en) * 2007-02-23 2008-08-28 Ibis Biosciences, Inc. Methods for rapid forensic dna analysis
WO2008118809A1 (en) * 2007-03-23 2008-10-02 Ibis Biosciences, Inc. Compositions for use in identification of mixed populations of bioagents
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
FR2917095B1 (en) * 2007-06-07 2009-07-17 Biomerieux Sa DEVICE FOR LYING MICROORGANISMS PRESENT IN AN ENVIRONMENTAL OR CLINICAL SAMPLE AND EXTRACTING NUCLEIC ACIDS FROM SAID MICROORGANISMS FOR ANALYSIS.
US8454906B2 (en) * 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
US20090126514A1 (en) * 2007-09-05 2009-05-21 Eric Gregory Burroughs Devices for collection and preparation of biological agents
EP2056114A1 (en) * 2007-10-29 2009-05-06 Koninklijke Philips Electronics N.V. Automatic detection of infectious diseases
US20090253181A1 (en) * 2008-01-22 2009-10-08 Microchip Biotechnologies, Inc. Universal sample preparation system and use in an integrated analysis system
EP2291541A4 (en) * 2008-03-05 2011-06-22 Clean Earth Tech Llc Multiplexed pcr-coupled pna labeled beads flow cytometric assay for simultaneous detection of multiple biological agents
WO2010009426A2 (en) * 2008-07-17 2010-01-21 Life Technologies Corporation Devices and methods for reagent delivery
US20110263044A1 (en) * 2008-07-31 2011-10-27 Eads Deutschland Gmbh Device and method for the automatic detection of biological particles
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
EP2347254A2 (en) 2008-09-16 2011-07-27 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
FR2939445B1 (en) 2008-12-10 2013-05-03 Biomerieux Sa AUTOMATED LYSE SYSTEM OF MICROORGANISMS PRESENT IN SAMPLE, NUCLEIC ACID EXTRACTION AND PURIFICATION OF MICROORGANISMS FOR ANALYSIS
CN102341691A (en) * 2008-12-31 2012-02-01 尹特根埃克斯有限公司 Instrument with microfluidic chip
WO2010093943A1 (en) * 2009-02-12 2010-08-19 Ibis Biosciences, Inc. Ionization probe assemblies
JP4870243B2 (en) * 2009-04-01 2012-02-08 新日本製鐵株式会社 Apparatus and method for continuous measurement of dust horizontal flux in the atmosphere
WO2010113521A1 (en) * 2009-04-01 2010-10-07 新日本製鐵株式会社 Horizontal component catcher of dustfall in atmosphere and measuring method of horizontal component
US8388908B2 (en) * 2009-06-02 2013-03-05 Integenx Inc. Fluidic devices with diaphragm valves
CA2764464A1 (en) * 2009-06-05 2010-12-09 Integenx Inc. Universal sample preparation system and use in an integrated analysis system
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
WO2011008971A1 (en) * 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
US20110091882A1 (en) * 2009-10-02 2011-04-21 Ibis Biosciences, Inc. Determination of methylation status of polynucleotides
US8717164B2 (en) * 2009-10-09 2014-05-06 Wind Willie, Llc Integrated security system for warning of dangerous substances that are dispersed by winds
US9890408B2 (en) * 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US8584703B2 (en) 2009-12-01 2013-11-19 Integenx Inc. Device with diaphragm valve
FR2957150A1 (en) * 2010-03-05 2011-09-09 Nosoco Tech METHOD AND APPARATUS FOR DETECTION IN CONTINUOUS AND IN REALLY REAL TIME OF TRACES OF MICROBES (BACTERIA, VIRUSES) OR DANGEROUS OR ILLEGAL SUBSTANCES (EXPLOSIVES, DRUGS) IN AN ATMOSPHERE
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
PL2556171T3 (en) 2010-04-05 2016-04-29 Prognosys Biosciences Inc Spatially encoded biological assays
US8512538B2 (en) 2010-05-28 2013-08-20 Integenx Inc. Capillary electrophoresis device
EP2606154B1 (en) 2010-08-20 2019-09-25 Integenx Inc. Integrated analysis system
US8763642B2 (en) 2010-08-20 2014-07-01 Integenx Inc. Microfluidic devices with mechanically-sealed diaphragm valves
NL2006600C2 (en) * 2011-02-11 2012-08-14 Dutch Water Technologies B V DEVICE AND METHOD FOR DETECTING TRACKS
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US8380541B1 (en) 2011-09-25 2013-02-19 Theranos, Inc. Systems and methods for collecting and transmitting assay results
DE102011053758A1 (en) * 2011-09-19 2013-03-21 BMA-Labor Gbr Method of analyzing air for the presence of biological substances
US10865440B2 (en) 2011-10-21 2020-12-15 IntegenX, Inc. Sample preparation, processing and analysis systems
US20150136604A1 (en) 2011-10-21 2015-05-21 Integenx Inc. Sample preparation, processing and analysis systems
US9110029B2 (en) 2012-06-25 2015-08-18 Diagnostic Consulting Network, Inc. Kits and methods for cyanide detection
JP6075979B2 (en) * 2012-06-27 2017-02-08 リオン株式会社 Particle counting system
US10519434B2 (en) 2012-07-13 2019-12-31 Diomics Corporation Biologic sample collection devices and methods of production and use thereof
US20140046722A1 (en) * 2012-08-10 2014-02-13 Sample6 Technologies, Inc. System for on-site environment monitoring
JP6033643B2 (en) * 2012-11-07 2016-11-30 アズビル株式会社 Variable channel width virtual impactor
SG11201506421PA (en) 2013-02-18 2015-09-29 Theranos Inc Systems and methods for collecting and transmitting assay results
US9169521B1 (en) * 2013-03-14 2015-10-27 The Boeing Company Point-of-collection sample preparation device and method
WO2014210225A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
WO2015073999A1 (en) 2013-11-18 2015-05-21 Integenx Inc. Cartridges and instruments for sample analysis
US9454921B2 (en) 2014-03-24 2016-09-27 Wind Willie, Llc Integrated security system for warning of dangerous substances that are dispersed by winds
DE102014105437A1 (en) * 2014-04-16 2015-10-22 Amodia Bioservice Gmbh Microfluidic module and cassette for immunological and molecular diagnostics in an automated analyzer
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
US20160025603A1 (en) 2014-07-22 2016-01-28 Diomics Corporation Airborne agent collectors, methods, systems and devices for monitoring airborne agents
WO2016025021A1 (en) 2014-08-15 2016-02-18 Diomics Corporation Films for biologic analyte collection and analysis and methods of production and use thereof
CN107106983B (en) 2014-10-22 2021-04-16 尹特根埃克斯有限公司 Systems and methods for sample preparation, processing, and analysis
HUP1500115A2 (en) * 2015-03-17 2018-02-28 Brg Radiotechnikai Gepgyar Kft Device and method for collecting samples
EP3901282B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
JP6352894B2 (en) * 2015-12-24 2018-07-04 トヨタ自動車株式会社 Solar cell module
NL2017001B1 (en) * 2016-06-20 2018-01-04 Prodrive Tech Bv Sensor system for sensing particle mass concentration in air, splitter unit, dual light beam unit, sensor unit and method for operating the latter
EP3333563A1 (en) * 2016-12-12 2018-06-13 Partanen, Tuomo System and method for determining an amount of fungal particles in air
WO2019147525A1 (en) 2018-01-26 2019-08-01 Advanced Electrofluidic Systems, Llc Method and apparatus for isolating and detecting biological and other particles
US11255794B1 (en) 2018-02-22 2022-02-22 Intelligent Optical Systems, Inc. Multi-substrate passive colorimetric sensors for detecting toxic industrial chemicals and chemical warfare agents
EP4153775A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11011277B1 (en) * 2020-06-02 2021-05-18 Sean Kelly Heat maps of infectious agents and methods of using same to screen subjects and/or determine an infection risk
US20220152614A1 (en) * 2020-11-16 2022-05-19 Koninklijke Fabriek Inventum B.V. Aircraft galley insert with pathogens diagnostic test capabilities
EP4001887A1 (en) * 2020-11-16 2022-05-25 Koninklijke Fabriek Inventum B.V. Methods of obtaining a biological sample representative of a passenger cabin on an aircraft using an air cyclonic collector via a cabin exhaust valve, and systems
CN114045217B (en) * 2022-01-11 2022-04-19 至美时代生物智能科技(北京)有限公司 Air microorganism sampling device and air microorganism sampling and detecting integrated device
CN114594208A (en) * 2022-03-07 2022-06-07 谱瑞前海(深圳)智能科技有限公司 Real-time detection device for virus spread to epidemic disease in air environment

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812370A (en) * 1971-09-07 1974-05-21 Environment One Corp Low cost portable room air cleaner
US5040424A (en) * 1988-07-21 1991-08-20 Regents Of The University Of Minnesota High volume PM10 sampling inlet
US5902385A (en) * 1997-06-23 1999-05-11 Skc, Inc. Swirling aerosol collector
US6270973B1 (en) * 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US20020018211A1 (en) * 2000-06-07 2002-02-14 Megerle Clifford A. System and method to detect the presence of a target organism within an air sample using flow cytometry
US6468330B1 (en) * 1999-06-14 2002-10-22 Innovatek, Inc. Mini-cyclone biocollector and concentrator
US20020182657A1 (en) * 2001-05-30 2002-12-05 Ranger Hubert O. Pathogen detection system for drinking water
US20020187470A1 (en) * 1998-06-24 2002-12-12 Casey Warren Michael Detection of single nucleotide polymorphisms
US20030003441A1 (en) * 2001-06-12 2003-01-02 The Regents Of The University Of California Portable pathogen detection system
US6508864B2 (en) * 1999-05-15 2003-01-21 Graseby Dynamics Limited Separation and collection of analyte materials
US20030022012A1 (en) * 2000-02-23 2003-01-30 Howmet Research Corporation Thermal barrier coating method and article
US20030032172A1 (en) * 2001-07-06 2003-02-13 The Regents Of The University Of California Automated nucleic acid assay system
US6520034B1 (en) * 2002-04-03 2003-02-18 The Regents Of The University Of California High air volume to low liquid volume aerosol collector
US20030036054A1 (en) * 2000-04-17 2003-02-20 Purdue Research Foundation Biosensor and related method
US20030064362A1 (en) * 2001-09-28 2003-04-03 Silver Robert B. Biosensor for detection of toxic substances
US20030085348A1 (en) * 2001-10-01 2003-05-08 Lockheed Martin Corporation Security system for NBC-safe building
US6576459B2 (en) * 2001-03-23 2003-06-10 The Regents Of The University Of California Sample preparation and detection device for infectious agents
US20030153021A1 (en) * 2001-12-06 2003-08-14 Arbor Vita Corporation Effective monitoring system for anthrax smallpox, or other pathogens
US20040020266A1 (en) * 2002-07-31 2004-02-05 Lockheed Martin Corporation System and method for biohazard detection using compression
US6688187B1 (en) * 2002-09-10 2004-02-10 The Regents Of The University Of California Aerosol sampling system
US20040028561A1 (en) * 2001-11-09 2004-02-12 Lockheed Martin Corporation System for the detection of pathogens in the mail stream
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US20040043443A1 (en) * 1999-11-08 2004-03-04 Peter Lejeune System, method and apparatus for the rapid detection and analysis of airborne biological agents
US6787104B1 (en) * 2000-09-14 2004-09-07 The Regents Of The University Of California Detection and treatment of chemical weapons and/or biological pathogens

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL287532A (en) * 1962-01-23
US3604814A (en) * 1969-06-20 1971-09-14 Technicon Corp Method and apparatus for the sequential analysis of fluid samples
DK150802C (en) * 1974-09-16 1988-02-01 Bifok Ab METHOD AND APPARATUS FOR CONTINUOUS HIGH-SPEED ANALYSIS OF A LIQUID TEST IN A BEARING FLOW
US4315754A (en) * 1979-08-28 1982-02-16 Bifok Ab Flow injection analysis with intermittent flow
JPS6146444U (en) * 1984-08-29 1986-03-28 工業技術院長 dust sampler
JPH05184350A (en) * 1992-01-16 1993-07-27 Mitsubishi Heavy Ind Ltd System for automatic counting of bacterial cell suspending in air
JPH06265447A (en) * 1993-03-16 1994-09-22 Hitachi Ltd Trace quantity reactor and trace element measuring instrument therewith
DE4435107C1 (en) * 1994-09-30 1996-04-04 Biometra Biomedizinische Analy Miniaturized flow thermal cycler
US5861316A (en) * 1994-10-25 1999-01-19 Midwest Research Institute Continuous emission monitoring system
US5716852A (en) * 1996-03-29 1998-02-10 University Of Washington Microfabricated diffusion-based chemical sensor
US6524532B1 (en) * 1995-06-20 2003-02-25 The Regents Of The University Of California Microfabricated sleeve devices for chemical reactions
US5589136A (en) * 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
US5766958A (en) * 1995-09-12 1998-06-16 Sullivan; George D. Method for detecting and collecting infectious airborne microorganisms for rapid identification
US5741647A (en) * 1996-02-16 1998-04-21 Tam; Joseph Wing On Flow through nucleic acid hybridisation uses thereof and a device thereof
US5747349A (en) * 1996-03-20 1998-05-05 University Of Washington Fluorescent reporter beads for fluid analysis
US5968731A (en) 1996-12-10 1999-10-19 The Regents Of The University Of California Apparatus for automated testing of biological specimens
US6122396A (en) * 1996-12-16 2000-09-19 Bio-Tech Imaging, Inc. Method of and apparatus for automating detection of microorganisms
US6235471B1 (en) * 1997-04-04 2001-05-22 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6368871B1 (en) * 1997-08-13 2002-04-09 Cepheid Non-planar microstructures for manipulation of fluid samples
EP1179585B1 (en) * 1997-12-24 2008-07-09 Cepheid Device and method for lysis
US6369893B1 (en) * 1998-05-19 2002-04-09 Cepheid Multi-channel optical detection system
US6217636B1 (en) * 1998-03-13 2001-04-17 The Texas A&M University System Transpirated wall aerosol collection system and method
JP3587052B2 (en) * 1998-03-25 2004-11-10 株式会社日立製作所 Biological sample pretreatment method and apparatus therefor
US6897031B1 (en) * 1998-04-17 2005-05-24 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in exocytosis
WO1999066304A1 (en) * 1998-06-19 1999-12-23 California Institute Of Technology Trace level detection of analytes using artificial olfactometry
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6228657B1 (en) * 1998-09-29 2001-05-08 The United States Of America As Represented By The Secretary Of The Army Environmental material ticket reader and airborne hazard detection system
JP3642687B2 (en) * 1998-10-26 2005-04-27 ミドリ安全株式会社 Portable airborne sampler
US5989824A (en) * 1998-11-04 1999-11-23 Mesosystems Technology, Inc. Apparatus and method for lysing bacterial spores to facilitate their identification
US6100084A (en) * 1998-11-05 2000-08-08 The Regents Of The University Of California Micro-sonicator for spore lysis
US6729196B2 (en) * 1999-03-10 2004-05-04 Mesosystems Technology, Inc. Biological individual sampler
US6887710B2 (en) * 1998-11-13 2005-05-03 Mesosystems Technology, Inc. Robust system for screening mail for biological agents
US6337213B1 (en) * 1998-12-21 2002-01-08 The Regents Of The University Of California Apparatus and method for collection and concentration of respirable particles into a small fluid volume
US6431476B1 (en) * 1999-12-21 2002-08-13 Cepheid Apparatus and method for rapid ultrasonic disruption of cells or viruses
AU782343B2 (en) * 1999-05-28 2005-07-21 Cepheid Apparatus and method for analyzing a fluid sample
US6368870B1 (en) * 1999-06-04 2002-04-09 Hach Company Controlled diffusion analysis
US6471136B1 (en) 1999-06-29 2002-10-29 Carrier Corporation Biosensors for monitoring air conditioning and refrigeration processes
US6491872B1 (en) * 1999-09-17 2002-12-10 The United States Of America As Represented By The Secretary Of The Army Method and system for detecting and recording submicron sized particles
US6813017B1 (en) * 1999-10-20 2004-11-02 Becton, Dickinson And Company Apparatus and method employing incoherent light emitting semiconductor devices as particle detection light sources in a flow cytometer
US6699713B2 (en) * 2000-01-04 2004-03-02 The Regents Of The University Of California Polymerase chain reaction system
US6403037B1 (en) * 2000-02-04 2002-06-11 Cepheid Reaction vessel and temperature control system
ATE412774T1 (en) * 2000-02-16 2008-11-15 Illumina Inc PARALLEL GENOTYPING OF MULTIPLE PATIENT SAMPLES
AU6114501A (en) * 2000-05-03 2001-11-12 Jen Gau Jr Biological identification system with integrated sensor chip
EP1366182A2 (en) * 2000-05-04 2003-12-03 Syngenta Participations AG Assay for nucleic acid analysis
US7682837B2 (en) * 2000-05-05 2010-03-23 Board Of Trustees Of Leland Stanford Junior University Devices and methods to form a randomly ordered array of magnetic beads and uses thereof
WO2001089696A2 (en) * 2000-05-24 2001-11-29 Micronics, Inc. Microfluidic concentration gradient loop
AU9408801A (en) * 2000-08-07 2002-02-18 Genset Sa Schizophrenia related gene and protein
US6363803B1 (en) * 2000-08-07 2002-04-02 Elmer Hubers Vehicle mounted soil sampler
US6374684B1 (en) * 2000-08-25 2002-04-23 Cepheid Fluid control and processing system
US6402817B1 (en) * 2000-08-25 2002-06-11 The Regents Of The University Of California Low pressure drop, multi-slit virtual impactor
US6586233B2 (en) * 2001-03-09 2003-07-01 The Regents Of The University Of California Convectively driven PCR thermal-cycling
US20030095897A1 (en) * 2001-08-31 2003-05-22 Grate Jay W. Flow-controlled magnetic particle manipulation
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812370A (en) * 1971-09-07 1974-05-21 Environment One Corp Low cost portable room air cleaner
US5040424A (en) * 1988-07-21 1991-08-20 Regents Of The University Of Minnesota High volume PM10 sampling inlet
US5902385A (en) * 1997-06-23 1999-05-11 Skc, Inc. Swirling aerosol collector
US6270973B1 (en) * 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US20020187470A1 (en) * 1998-06-24 2002-12-12 Casey Warren Michael Detection of single nucleotide polymorphisms
US6508864B2 (en) * 1999-05-15 2003-01-21 Graseby Dynamics Limited Separation and collection of analyte materials
US6468330B1 (en) * 1999-06-14 2002-10-22 Innovatek, Inc. Mini-cyclone biocollector and concentrator
US20040043443A1 (en) * 1999-11-08 2004-03-04 Peter Lejeune System, method and apparatus for the rapid detection and analysis of airborne biological agents
US20030022012A1 (en) * 2000-02-23 2003-01-30 Howmet Research Corporation Thermal barrier coating method and article
US6716620B2 (en) * 2000-04-17 2004-04-06 Purdue Research Foundation Biosensor and related method
US20030036054A1 (en) * 2000-04-17 2003-02-20 Purdue Research Foundation Biosensor and related method
US20020018211A1 (en) * 2000-06-07 2002-02-14 Megerle Clifford A. System and method to detect the presence of a target organism within an air sample using flow cytometry
US6787104B1 (en) * 2000-09-14 2004-09-07 The Regents Of The University Of California Detection and treatment of chemical weapons and/or biological pathogens
US6576459B2 (en) * 2001-03-23 2003-06-10 The Regents Of The University Of California Sample preparation and detection device for infectious agents
US20020182657A1 (en) * 2001-05-30 2002-12-05 Ranger Hubert O. Pathogen detection system for drinking water
US20030027244A1 (en) * 2001-06-12 2003-02-06 The Regents Of The University Of California Portable pathogen detection system
US20030003441A1 (en) * 2001-06-12 2003-01-02 The Regents Of The University Of California Portable pathogen detection system
US20030032172A1 (en) * 2001-07-06 2003-02-13 The Regents Of The University Of California Automated nucleic acid assay system
US20030064362A1 (en) * 2001-09-28 2003-04-03 Silver Robert B. Biosensor for detection of toxic substances
US20030085348A1 (en) * 2001-10-01 2003-05-08 Lockheed Martin Corporation Security system for NBC-safe building
US20040028561A1 (en) * 2001-11-09 2004-02-12 Lockheed Martin Corporation System for the detection of pathogens in the mail stream
US20030153021A1 (en) * 2001-12-06 2003-08-14 Arbor Vita Corporation Effective monitoring system for anthrax smallpox, or other pathogens
US6520034B1 (en) * 2002-04-03 2003-02-18 The Regents Of The University Of California High air volume to low liquid volume aerosol collector
US20040020266A1 (en) * 2002-07-31 2004-02-05 Lockheed Martin Corporation System and method for biohazard detection using compression
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US6688187B1 (en) * 2002-09-10 2004-02-10 The Regents Of The University Of California Aerosol sampling system

Cited By (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US9052255B2 (en) 2002-08-26 2015-06-09 Lawrence Livermore National Security, Llc System for autonomous monitoring of bioagents
USRE46322E1 (en) 2003-03-14 2017-02-28 Lawrence Livermore National Security, Llc Method for chemical amplification based on fluid partitioning in an immiscible liquid
USRE48788E1 (en) 2003-03-14 2021-10-26 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning
USRE47080E1 (en) 2003-03-14 2018-10-09 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning
USRE43365E1 (en) 2003-03-14 2012-05-08 Lawrence Livermore National Security, Llc Apparatus for chemical amplification based on fluid partitioning in an immiscible liquid
USRE41780E1 (en) 2003-03-14 2010-09-28 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning in an immiscible liquid
USRE45539E1 (en) 2003-03-14 2015-06-02 Lawrence Livermore National Security, Llc Method for chemical amplification based on fluid partitioning in an immiscible liquid
US20100015601A1 (en) * 2004-11-24 2010-01-21 Invitrogen Corporation Biological confirmation and detection system
US20070053188A1 (en) * 2005-09-06 2007-03-08 Luminator Holding, L.P. LED ultraviolet air sanitizer light fixture
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection
US7858366B2 (en) 2006-08-24 2010-12-28 Microfluidic Systems, Inc Integrated airborne substance collection and detection system
WO2008097250A3 (en) * 2006-08-24 2008-10-16 Microfluidic Systems Inc An integrated airborne substance collection and detection system
WO2008108792A3 (en) * 2006-08-24 2008-10-30 Microfluidic Systems Inc An integrated airborne substance collection and detection system
WO2008108791A3 (en) * 2006-08-24 2008-10-30 Microfluidic Systems Inc An integrated airborne substance collection and detection system
US7633606B2 (en) 2006-08-24 2009-12-15 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20080048874A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20100050742A1 (en) * 2006-08-24 2010-03-04 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
WO2008108792A2 (en) * 2006-08-24 2008-09-12 Microfluidic Systems, Inc. An integrated airborne substance collection and detection system
US7705739B2 (en) 2006-08-24 2010-04-27 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
WO2008108791A2 (en) * 2006-08-24 2008-09-12 Microfluidic Systems, Inc. An integrated airborne substance collection and detection system
US20080168752A1 (en) * 2006-12-22 2008-07-17 Perma Pure, Llc Separating particulate-containing gas flow into particulate and non-particulate flow portions
US20080166793A1 (en) * 2007-01-04 2008-07-10 The Regents Of The University Of California Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US8338166B2 (en) 2007-01-04 2012-12-25 Lawrence Livermore National Security, Llc Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US20080183433A1 (en) * 2007-01-30 2008-07-31 The Regents Of The University Of California Detection and quantification system for monitoring instruments
US7412356B1 (en) 2007-01-30 2008-08-12 Lawrence Livermore National Security, Llc Detection and quantification system for monitoring instruments
US20080254467A1 (en) * 2007-03-02 2008-10-16 John Frederick Regan Automated High-Throughput Flow-Through Real-Time Diagnostic System
US8298763B2 (en) 2007-03-02 2012-10-30 Lawrence Livermore National Security, Llc Automated high-throughput flow-through real-time diagnostic system
US11366106B2 (en) 2007-10-02 2022-06-21 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US10634667B2 (en) 2007-10-02 2020-04-28 Theranos Ip Company, Llc Modular point-of-care devices, systems, and uses thereof
US11199538B2 (en) 2007-10-02 2021-12-14 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US11143647B2 (en) 2007-10-02 2021-10-12 Labrador Diagnostics, LLC Modular point-of-care devices, systems, and uses thereof
US11137391B2 (en) 2007-10-02 2021-10-05 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US11092593B2 (en) 2007-10-02 2021-08-17 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US11899010B2 (en) 2007-10-02 2024-02-13 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US11061022B2 (en) 2007-10-02 2021-07-13 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US8697377B2 (en) 2007-10-02 2014-04-15 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US10900958B2 (en) 2007-10-02 2021-01-26 Labrador Diagnostics Llc Modular point-of-care devices, systems, and uses thereof
US10670588B2 (en) 2007-10-02 2020-06-02 Theranos Ip Company, Llc Modular point-of-care devices, systems, and uses thereof
US9435793B2 (en) 2007-10-02 2016-09-06 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US8822167B2 (en) 2007-10-02 2014-09-02 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US9121851B2 (en) 2007-10-02 2015-09-01 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US9588109B2 (en) 2007-10-02 2017-03-07 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US9581588B2 (en) 2007-10-02 2017-02-28 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US9012163B2 (en) 2007-10-02 2015-04-21 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US9285366B2 (en) 2007-10-02 2016-03-15 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
US20090263794A1 (en) * 2008-04-21 2009-10-22 Shanavaz Nasarabadi High Throughput Flow Through Sample Preparation Using Magnetic Beads
US7867713B2 (en) 2008-04-21 2011-01-11 Lawrence Livermore National Security, Llc Polymerase chain reaction system using magnetic beads for analyzing a sample that includes nucleic acid
US20100050749A1 (en) * 2008-08-28 2010-03-04 MicroFluidic Systems, Ltd. Sample preparation apparatus
US8133451B2 (en) 2008-08-28 2012-03-13 Microfluidic Systems, Inc. Sample preparation apparatus
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US20110092376A1 (en) * 2008-09-23 2011-04-21 Quantalife, Inc. System for droplet-based assays using an array of emulsions
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9216392B2 (en) 2008-09-23 2015-12-22 Bio-Rad Laboratories, Inc. System for forming an array of emulsions
US9649635B2 (en) 2008-09-23 2017-05-16 Bio-Rad Laboratories, Inc. System for generating droplets with push-back to remove oil
US9243288B2 (en) 2008-09-23 2016-01-26 Bio-Rad Laboratories, Inc. Cartridge with lysis chamber and droplet generator
US11130134B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Method of performing droplet-based assays
US9248417B2 (en) 2008-09-23 2016-02-02 Bio-Rad Laboratories, Inc. System for droplet-based assays using an array of emulsions
US9636682B2 (en) 2008-09-23 2017-05-02 Bio-Rad Laboratories, Inc. System for generating droplets—instruments and cassette
US10279350B2 (en) 2008-09-23 2019-05-07 Bio-Rad Laboratories, Inc. Method of generating droplets
US11633739B2 (en) 2008-09-23 2023-04-25 Bio-Rad Laboratories, Inc. Droplet-based assay system
US10258989B2 (en) 2008-09-23 2019-04-16 Bio-Rad Laboratories, Inc. Method of making a device for generating droplets
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US11612892B2 (en) 2008-09-23 2023-03-28 Bio-Rad Laboratories, Inc. Method of performing droplet-based assays
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9126160B2 (en) 2008-09-23 2015-09-08 Bio-Rad Laboratories, Inc. System for forming an array of emulsions
US10258988B2 (en) 2008-09-23 2019-04-16 Bio-Rad Laboratories, Inc. Device for generating droplets
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US20110212516A1 (en) * 2008-09-23 2011-09-01 Ness Kevin D Flow-based thermocycling system with thermoelectric cooler
US9623384B2 (en) 2008-09-23 2017-04-18 Bio-Rad Laboratories, Inc. System for transporting emulsions from an array to a detector
US20110086780A1 (en) * 2008-09-23 2011-04-14 Quantalife, Inc. System for forming an array of emulsions
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US10677693B2 (en) 2009-09-02 2020-06-09 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
US10166522B2 (en) 2009-09-02 2019-01-01 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
US20110053798A1 (en) * 2009-09-02 2011-03-03 Quantalife, Inc. System for mixing fluids by coalescence of multiple emulsions
US9194861B2 (en) 2009-09-02 2015-11-24 Bio-Rad Laboratories, Inc. Method of mixing fluids by coalescence of multiple emulsions
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US11060136B2 (en) 2010-03-02 2021-07-13 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US11866771B2 (en) 2010-03-02 2024-01-09 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US10378048B2 (en) 2010-03-02 2019-08-13 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US9393560B2 (en) 2010-03-25 2016-07-19 Bio-Rad Laboratories, Inc. Droplet transport system for detection
US10744506B2 (en) 2010-03-25 2020-08-18 Bio-Rad Laboratories, Inc. Device for generating droplets
US9500664B2 (en) 2010-03-25 2016-11-22 Bio-Rad Laboratories, Inc. Droplet generation for droplet-based assays
US10099219B2 (en) 2010-03-25 2018-10-16 Bio-Rad Laboratories, Inc. Device for generating droplets
US8730479B2 (en) 2010-03-25 2014-05-20 Bio-Rad Laboratories, Inc. Detection system for droplet-based assays
US10272432B2 (en) 2010-03-25 2019-04-30 Bio-Rad Laboratories, Inc. Device for generating droplets
US9089844B2 (en) 2010-11-01 2015-07-28 Bio-Rad Laboratories, Inc. System for forming emulsions
US11199489B2 (en) 2011-01-20 2021-12-14 Labrador Diagnostics Llc Systems and methods for sample use maximization
US9677993B2 (en) 2011-01-21 2017-06-13 Theranos, Inc. Systems and methods for sample use maximization
US10876956B2 (en) 2011-01-21 2020-12-29 Labrador Diagnostics Llc Systems and methods for sample use maximization
US10557786B2 (en) 2011-01-21 2020-02-11 Theranos Ip Company, Llc Systems and methods for sample use maximization
US9464981B2 (en) 2011-01-21 2016-10-11 Theranos, Inc. Systems and methods for sample use maximization
US11644410B2 (en) 2011-01-21 2023-05-09 Labrador Diagnostics Llc Systems and methods for sample use maximization
US9222128B2 (en) 2011-03-18 2015-12-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
US10760073B2 (en) 2011-04-25 2020-09-01 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9347059B2 (en) 2011-04-25 2016-05-24 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10190115B2 (en) 2011-04-25 2019-01-29 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9885034B2 (en) 2011-04-25 2018-02-06 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US8663920B2 (en) 2011-07-29 2014-03-04 Bio-Rad Laboratories, Inc. Library characterization by digital assay
US11162936B2 (en) 2011-09-13 2021-11-02 Labrador Diagnostics Llc Systems and methods for multi-analysis
US10018643B2 (en) 2011-09-25 2018-07-10 Theranos Ip Company, Llc Systems and methods for multi-analysis
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US10534009B2 (en) 2011-09-25 2020-01-14 Theranos Ip Company, Llc Systems and methods for multi-analysis
US10557863B2 (en) 2011-09-25 2020-02-11 Theranos Ip Company, Llc Systems and methods for multi-analysis
US10371710B2 (en) 2011-09-25 2019-08-06 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US10627418B2 (en) 2011-09-25 2020-04-21 Theranos Ip Company, Llc Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9952240B2 (en) 2011-09-25 2018-04-24 Theranos Ip Company, Llc Systems and methods for multi-analysis
US9128015B2 (en) 2011-09-25 2015-09-08 Theranos, Inc. Centrifuge configurations
US9719990B2 (en) 2011-09-25 2017-08-01 Theranos, Inc. Systems and methods for multi-analysis
US10976330B2 (en) 2011-09-25 2021-04-13 Labrador Diagnostics Llc Fluid handling apparatus and configurations
US11524299B2 (en) 2011-09-25 2022-12-13 Labrador Diagnostics Llc Systems and methods for fluid handling
US11009516B2 (en) 2011-09-25 2021-05-18 Labrador Diagnostics Llc Systems and methods for multi-analysis
US11054432B2 (en) 2011-09-25 2021-07-06 Labrador Diagnostics Llc Systems and methods for multi-purpose analysis
US9592508B2 (en) 2011-09-25 2017-03-14 Theranos, Inc. Systems and methods for fluid handling
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US10518265B2 (en) 2011-09-25 2019-12-31 Theranos Ip Company, Llc Systems and methods for fluid handling
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9645143B2 (en) 2011-09-25 2017-05-09 Theranos, Inc. Systems and methods for multi-analysis
US8435738B2 (en) * 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US20130079236A1 (en) * 2011-09-25 2013-03-28 Theranos, Inc., a Delaware Corporation Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
US8994556B2 (en) 2012-05-24 2015-03-31 Douglas H. Lundy Threat detection system and method
CN105378450B (en) * 2013-02-18 2022-06-07 赛拉诺斯知识产权有限责任公司 System and method for multivariate analysis
US11385252B2 (en) 2013-02-18 2022-07-12 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
CN105378450A (en) * 2013-02-18 2016-03-02 赛拉诺斯股份有限公司 Systems and methods for multi-analysis
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
WO2014127379A1 (en) * 2013-02-18 2014-08-21 Theranos, Inc. Systems and methods for multi-analysis
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
US10509029B2 (en) * 2014-05-28 2019-12-17 Tokyo Electron Limited Measurement device and measurement method
US20170191993A1 (en) * 2014-05-28 2017-07-06 Tokyo Electron Limited Measurement Device and Measurement Method

Also Published As

Publication number Publication date
US9052255B2 (en) 2015-06-09
AU2003304254A1 (en) 2005-01-13
US20050239192A1 (en) 2005-10-27
WO2005001435A3 (en) 2005-08-11
US20040038385A1 (en) 2004-02-26
EP1576353A2 (en) 2005-09-21
US20110027781A1 (en) 2011-02-03
AU2003304254B2 (en) 2008-11-20
WO2005001435A2 (en) 2005-01-06
JP2006508371A (en) 2006-03-09
CA2496128A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
US20060057599A1 (en) System for autonomous monitoring of bioagents
Hindson et al. APDS: the autonomous pathogen detection system
EP1692673B1 (en) Autonomous surveillance system
US20150322500A1 (en) Multiplexed diagnostic platform for point-of care pathogen detection
US6688187B1 (en) Aerosol sampling system
US20100015601A1 (en) Biological confirmation and detection system
McBride et al. Autonomous Detection of Aerosolized Bacillus a nthracis and Yersinia p estis
US7858366B2 (en) Integrated airborne substance collection and detection system
CA2470632A1 (en) System, method and apparatus for the rapid detection and analysis of airborne biological agents
WO2008108792A2 (en) An integrated airborne substance collection and detection system
US7503230B2 (en) Biobriefcase aerosol collector heater
US7591197B2 (en) Biobriefcase aerosol collector
US7503229B2 (en) Biobriefcase electrostatic aerosol collector
US20060281101A1 (en) Biobriefcase
Milanovich et al. Apds, a Network-Ready, Broad Spectrum, Environmental Pathogen Detection System
US8173431B1 (en) Mail screening to detect mail contaminated with biological harmful substances
US7183104B1 (en) Separator and particle detection system
Belgrader et al. Autonomous system for pathogen detection and identification
Mariella Jr et al. Autonomous System for Pathogen Detection and Identification
Hindson et al. Autonomous detection of aerosolized biological agents by multiplexed immunoassay with PCR confirmation
Hazi Detecting Bioaerosols When Time Is of the Essence
Bailey BioBriefcase R&D100 Award submission.

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, CAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DZENTIS, JOHN;BROWN, STEVE B.;COLSTON, JR. BILLY W.;AND OTHERS;REEL/FRAME:016043/0353;SIGNING DATES FROM 20041102 TO 20041120

AS Assignment

Owner name: ENERGY, U.S. DEPARTMENT OF, DISTRICT OF COLUMBIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:016136/0059

Effective date: 20050408

AS Assignment

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, CALIFOR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:020012/0032

Effective date: 20070924

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,CALIFORN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:020012/0032

Effective date: 20070924

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION